GALECTIN-9-SECRETING CELL, AND PRODUCTION METHOD AND USE OF THE SAME
The object of the present invention is to provide a cell that can exhibit physiological activity based on galectin-9, a method for producing the cell, and use of the cell. In order to achieve the above object, the cell of the present invention contains galectin-9, and the galectin-9 is expressed on a cell surface.
The present invention relates to galectin-9-secreting cell, a method for producing the cell, and use of the cell. For example, the present invention relates to a CD4 T cell that secretes galectin-9 and techniques applying the CD4 T cell.
BACKGROUND ARTGalectin-9 (Gal-9) is a member of the galectin family, and exhibits physiological activity upon binding to β galactoside of N- or O-glycan (Non-Patent Document 1). Galectin-9 was first discovered and identified as a T cell apoptosis-inducing factor (Non-Patent Document 2) and an eosinophil chemotactic factor (Non-Patent Document 3). From then on, a wide variety of activities of galectin-9 have been reported up to the present. Galectin-9 acts on T cells in the following manner: galectin-9 binds to Tim-3 to induce apoptosis of Tim-3 positive TH1 cells, thereby settling down excess TH1 reactions to inhibit autoimmune inflammation (Non-Patent Document 4). A TH17 cell is considered to be a cause or one of exacerbating factors of various intractable diseases such as autoimmune diseases, allergies, and cancers, and this cell also expresses Tim-3 (Non-Patent Documents 5 to 6). Administration of galectin-9 decreases TH17 cells, and increases inflammation inhibitory Treg cells (Non-Patent Document 7). At present, involvement of Tim-3 in this decrease in TH17 cells and the mechanism by which such decrease occurs are unknown.
As actions of galectin-9 on cells other than T cells, the following actions are known in addition to the above-described eosinophilotactic activity: induction of CD11bLy-6C monocytic myeloid-derived suppressor cells (Non-Patent Document 8); induction of CD11bLy-6G neutrophilic myeloid-derived suppressor cells (Non-Patent Documents 9 to 10); induction of plasmacytoid dendritic cells (Non-Patent Document 11); and inhibition of degranulation from mast cells (Non-Patent Document 12). Many of previous reports focus on the action of galectin-9 for inhibiting exaggerated immunoreactions. However, in some situations, galectin-9 enhances immunity. Galectin-9 binds to Tim-3 on monocytes and dendritic cells to activate these cells, thereby promoting the production of inflammatory cytokines (Non-Patent Document 13). Also, when galectin-9 interacts with Tim-3 in macrophages, immunity for eliminating tubercle bacilli is enhanced
- (Non-Patent Document 14). That is to say, galectin-9 can modulate immunity bidirectionally.
- Patent Document 1: WO 2005/09306
- Non-Patent Document 1: Hirabayashi, J. et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta, 1572, 232-254 (2002)
- Non-Patent Document 2: Wada, J., Ota, K., Kumar, A., Wallner, E. I. & Kanwar, Y. S. Developmental regulation, expression, and apoptotic potential of galectin-9, a β-galactoside binding lectin. J Clin Invest, 99, 2452-2461 (1997)
- Non-Patent Document 3: Matsumoto, R. et al. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem, 273, 16976−16984 (1998)
- Non-Patent Document 4: Zhu, C. et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol, 6, 1245-1252 (2005)
- Non-Patent Document 5: Chen, Y. et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest, 116, 1317-1326 (2006)
- Non-Patent Document 6: Nakae, S., Iwakura, Y., Suto, H. & Galli, S. J. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol, 81, 1258-1268 (2007)
- Non-Patent Document 7: Seki, M. et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol, 127, 78-88 (2008)
- Non-Patent Document 8: Arikawa, T. et al. Galectin-9 expands immunosuppressive macrophages to ameliorate T-cell-mediated lung inflammation. Eur J Immunol, 40, 548-558 (2010)
- Non-Patent Document 9: Tsuboi, Y. et al. Galectin-9 protects mice from the Shwartzman reaction by attracting prostaglandin E2-producing polymorphonuclear leukocytes. Clin Immunol, 124, 221-233 (2007)
- Non-Patent Document 10: Dardalhon, V. et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+myeloid cells. J Immunol, 185, 1383-1392 (2010)
- Non-Patent Document 11: Nobumoto, A. et al. Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumor-bearing mice. Clin Immunol, 130, 322-330 (2009)
- Non-Patent Document 12: Niki, T. et al. Galectin-9 is a high affinity IgE-binding lectin with anti-allergic effect by blocking IgE-antigen complex formation. J Biol Chem, 284, 32344-32352 (2009)
- Non-Patent Document 13: Anderson, A. C. et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science, 318, 1141-1143 (2007)
- Non-Patent Document 14: Jayaraman, P. Tim3 binding to galectin-9 stimulates antimicrobial immunity. J Exp Med, 207, 2343-2354 (2010)
- Non-Patent Document 15: Katoh, S. et al. Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am J Respir Crit Care Med, 176, 27-35 (2007)
- Non-Patent Document 16: Nobumoto, A. et al. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology, 18, 735-744 (2008)
- Non-Patent Document 17: Mishra, R. et al. Galectin-9 trafficking regulates apical-basal polarity in Madin-Darby canine kidney epithelial cells. Proc Natl Acad Sci USA, 107, 17633-17638 (2010)
- Non-Patent Document 18: Tanikawa, R. et al. Galectin-9 induces osteoblast differentiation through the CD44/Smad signaling pathway. Biochem Biophys Res Commun 394, 317-322 (2010)
- Non-Patent Document 19: Chabot, S. et al. Regulation of galectin-9 expression and release in Jurkat T cell line cells. Glycobiology, 12, 111-118 (2002)
- Non-Patent Document 20: Fujio, K., Okamura, T. & Yamamoto, K. The Family of IL-10-secreting CD4+ T cells. Adv Immunol, 105, 99-130 (2010)
- Non-Patent Document 21: Ochi, H. et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25−LAP+ T cells. Nat Med, 12, 627-635 (2006)
- Non-Patent Document 22: Okamura, T. et al. CD4+CD25−LAG3+ regulatory T cells controlled by the transcription factor Egr-2. Proc Natl Acad Sci USA, 106, 13974-13979 (2009)
- Non-Patent Document 23: Wakkach, A. et al. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity, 18, 605−617 (2003)
- Non-Patent Document 24: Jangpatarapongsa, K. et al. Plasmodium vivax parasites alter the balance of myeloid and plasmacytoid dendritic cells and the induction of regulatory T cells. Eur J Immunol, 38, 2697-2705 (2008)
- Non-Patent Document 25: Kavousanaki, M., Makrigiannakis, A., Boumpas, D. & Verginis, P. Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10-producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy. Arthritis Rheum, 62, 53-63 (2010)
- Non-Patent Document 26: Awasthi, A. et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol, 8, 1380-1389 (2007)
- Non-Patent Document 27: Stumhofer, J. S. et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol, 8, 1363-1371 (2007)
- Non-Patent Document 28: Fitzgerald, D. C. et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol, 8, 1372-1379 (2007)
- Non-Patent Document 29: Barrat, F. J. et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med, 195, 603-616 (2002)
- Non-Patent Document 30: Uhlig, H. H. et al. Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol, 177, 5852−5860 (2006)
- Non-Patent Document 31: Maynard, C. L. et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3− precursor cells in the absence of interleukin 10. Nat Immunol, 8, 931-941 (2007)
- Non-Patent Document 32: Nagahara, K. et al. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol, 181, 7660-7669 (2008)
- Non-Patent Document 33: Nishi, N. et al. Development of highly stabilized galectins: truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett, 579, 2058-2064 (2005)
- Non-Patent Document 34: Seki, M. et al. Beneficial effect of galectin-9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts. Arthritis Rheum, 56, 3968-3976 (2007)
- Non-Patent Document 35: Wilson, N. J. et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol, 8, 950-957 (2007)
- Non-Patent Document 36: Oomizu, S. et al. Oral administration of pulverized Konjac glucomannan prevents the increase of plasma immunoglobulin E and immunoglobulin G levels induced by the injection of syngeneic keratinocyte extracts in BALB/c mice. Clin. Exp. Allergy, 36, 102-110 (2006)
- Non-Patent Document 37: Lu, L. H. et al: Characterization of galectin-9-induced death of Jurkat T cells. J Biochem, 141, 157-172 (2007)
- Non-Patent Document 38: Park, H. et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol, 6, 1133-1141 (2005)
- Non-Patent Document 39: Laurence, A. et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity, 26, 371-381 (2007)
- Non-Patent Document 40: Mills, K. H. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol, 38, 2636-2649 (2008)
- Non-Patent Document 41: Brun, V., Bastian, H., Neveu, V. & Foussat, A. Clinical grade production of IL-10 producing regulatory Tr1 lymphocytes for cell therapy of chronic inflammatory diseases. Int Immunopharmacol, 9, 609-613 (2009)
- Non-Patent Document 42: Levings, M. K. et al. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood, 105, 1162-1169 (2005)
- Non-Patent Document 43: Roncarolo, M. G. & Gregori, S. Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol, 38, 925-927 (2008)
- Non-Patent Document 44: Kojima, K. et al. Galectin-9 attenuates acute lung injury by expanding CD14-plasmacytoid dendritic cell-like macrophages. Am J Respir Crit. Care Med, 184, 328-339 (2011)
Clarification of the above-described galectin-9 activities was mostly achieved by administering or adding recombinant proteins. For example, administration of galectin-9 exhibits a therapeutic effect in mouse collagen-induced arthritis, where galectin-9 inhibits the decrease in Tim-3 positive T cells, the increase in Treg cells, and the production of inflammatory cytokines such as IFN-γ and IL-17 (Non-Patent Document 7). It is noteworthy that galectin-9 knockout mice are highly sensitive to rheumatoid arthritis-inducing stimulation, and in the galectin-9 knockout mice, Tim-3 positive CD4 T cells (TH1 and TH17) are increased and Treg cells are decreased as compared with those in wild-type mice (Non-Patent Document 7). These properties are consistent with the effects of galectin-9 clarified by the administration of recombinant proteins. Accordingly, it is obvious that galectin-9 is secreted as an endogenous immunoregulatory factor and adjusts immune balance. However, a cell that secretes galectin-9 or modulates immunity in vivo has not yet been identified.
Tim-3 is the most extensively studied target of galectin-9. However, all of the wide variety of galectin-9 activities cannot be explained with Tim-3. Indeed, up until the present, CD44 and integrin (which are adhesion factor for activated lymphocytes) and IgE have been identification as targets of galectin-9, and exaggerated immunoreactions by allergies and metastasis of cancer cells are inhibited via these targets (Non-Patent Documents 12, 15 to 16). It can be easily predicted that more targets of galectin-9 would be found in the future as the research advances. Exhibiting a variety of activities through interactions with a plurality of targets as described above is a common property among many lectins. By the way, the above-described targets of galectin-9 are all present on cell membranes. Thus, needless to say, the functions of galectin-9 is exhibited after it is secreted out of the cell and binds to these targets.
However, galectin-9 has no signal peptide and basically is located in the cytoplasm, and its roles in the cytoplasm or nucleus also have been reported (Non-Patent Documents 17 to 18). However, considering the presence of the targets on the cell membrane and the actions of galectin-9 as described above, there must be some galectin-9 secreted out of the cell. Actually, secretion of galectin-9 from a T cell- or mast cell-derived cell line has been reported (Non-Patent Documents 12 and 19). However, the secretion mechanism thereof is totally unknown. Also, since the reported origin of secretion is the cell line, there is no guarantee that cells of the same line similarly secrete galectin-9 in vivo. Most of all, the fact that cells expressing galectin-9 do not necessarily secrete the galectin-9 makes the identification of galectin-9 secreting cells particularly difficult.
Galectin-9 is an important immunoregulatory factor. If galectin-9 secreting cells can be identified, they are expected to be useful as indicators to examine immune balance, so that, for example, they can serve as surrogate markers for diagnosing various immune diseases or determining a therapeutic effect on the same. It is also expected that the galectin-9 secreting cells can be used in cell therapy when used in combination with a technique for purifying the cells, and there is a possibility that the cells can be applied to treatment of intractable diseases such as autoimmune diseases, allergies, and cancers.
As described above, although galectin-9 have a wide variety of immune regulatory activities, much about the details of their action mechanisms remains unknown. Also, cells etc. that secrete galectin-9 or regulate immunoreactions in vivo have not yet been identified. Clarification of the details of immune regulation, e.g., the details of differentiation control of TH17 and Treg cells, by galectin-9, or identification of cells that can exhibit physiological activity based on galectin-9, such as cells that secrete galectin-9 or regulate immunoreactions in vivo, has been desired.
With the foregoing in mind, it is an object of the present invention to provide a cell that can exhibit physiological activity based on galectin-9, a method for producing the cell, and use of the cell.
Means for Solving ProblemIn order to achieve the above object, the present invention provides a cell that contains galectin-9, characterized in that the galectin-9 is expressed on a cell surface.
The present invention provides, as a first production method of the cell according to the present invention, a method for producing the cell of the present invention, including: administering galectin-9 to an animal, thus inducing galectin-9 expression on a cell surface of at least one cell in the animal.
The present invention provides, as a second production method of the cell according to the present invention, a method for producing the cell of the present invention, including: culturing one or more cells of an animal in the presence of galectin-9, thus inducing galectin-9 expression on a cell surface of at least one of the cells.
The present invention also provides a pharmaceutical agent containing: at least one selected from the group consisting of the cell of the present invention; homogenates of the cell; and extracts of the cell.
The present invention also provides a method for diagnosing the presence or absence of galectin-9 or a galectin-9-binding substance in a test cell using at least one selected from the group consisting of the cell of the present invention; homogenates of the cell; and extracts of the cell.
The present invention also provides a method for treating a disease of an animal or reducing a symptom caused by the disease, including the step of administering to the animal at least one selected from the group consisting of the cell of the present invention; homogenates of the cell; and extracts of the cell.
The present invention also provides a method for regulating immunity of an animal, including the step of administering the cell of the present invention to the animal.
The present invention also provides a method for detecting the cell of the present invention, including the step of: detecting the galectin-9 expressed on the cell surface of the cell as a marker.
The present invention also provides a method for diagnosing a disease of an animal or a symptom caused by the disease, including the step of in a tissue of the animal containing or not containing the cell of the present invention, detecting the cell of the present invention qualitatively or quantitatively by the cell detection method of the present invention.
The present invention also provides a method for determining a therapeutic effect on a disease of an animal, including the steps of treating the disease of the animal; diagnosing the disease or a symptom caused by the disease by the diagnostic method of the present invention before and after the treatment; and comparing diagnostic results obtained before and after the treatment.
The present invention also provides a cell separation method including the steps of: in a tissue of an animal containing the cell of the present invention, detecting the cell by the cell detection method of the present invention; and separating the detected cell from other cells in the tissue of the animal.
Effects of the InventionAs described above, according to the present invention, it is possible to provide a cell that can exhibit physiological activity based on galectin-9, a method for producing the cell, and use of the cell.
(B)
(B)
(A) The cells cultured for 7 days in the presence of M-CSF or M-CSF and galectin-9 in the experiment described with reference to
(B) The mRNA expressions of transcription factors of the above-described cells were analyzed by real-time RT-PCR. The vertical axis of each graph in
(C) The mRNA expression of the Toll-like receptor of the above-described cells was analyzed by real-time RT-PCR. The vertical axis of
(D) Toll-like receptor agonists indicated in
(A)
(B) Macrophages differentiated with M-CSF and galectin-9 by the method of
(C)
(A) To pDC-like macrophages matured by being subjected to the LPS stimulation by the method of
(B)
The present invention will be described more specifically below. It should be noted, however, that the present invention is by no means limited by the following descriptions.
The inventors of the present invention conducted diligent studies, where they focused on clarification of the details of the immune regulation by galectin-9. In particular, they focused on clarification of the details of differentiation control of TH17 and Treg cells and identification of cells that secrete galectin-9 and regulate immunoreactions in vivo. As a result, the inventors of the present invention succeeded in identifying a novel galectin-9-secreting CD4 positive T cell (THGAL9 cell), and verified that this cell controls the differentiation of TH17 and Treg cells. Also, the inventors of the present invention discovered that the THGAL9 cells are increased in vitro by the addition of galectin-9. The THGAL9 cells not only express galectin-9 on cell surfaces but also express a known Tr1 cell marker, and secret IL-10. This suggests the possibility that the THGAL9 cells might be the same as the Tr1 cells according to the current definition or belong to a subpopulation of the Tr1 cells. In this case, galectin-9 also is useful as a Tr1 cell marker, and would play a very important role in purification of the Tr1 cells and application of the Tr1 cells to treatment. In the present invention, the term “cell surface” is not particularly limited, and may refer to a surface of a cell membrane on the side facing the outside of the cell, for example. That is, the phrase “the state where galectin-9 is expressed on a cell surface” may refer to, but not particularly limited to, the state where galectin-9 is expressed in a cell membrane or on a surface thereof with the whole or part of the galectin-9 being exposed to the outside of the cell, for example.
The inventors of the present invention verified, using a mouse EAE model as one of autoimmune disease models, that the TH17 cell differentiation inhibition and the Treg cell differentiation promotion by galectin-9 depend on IL-2 but do not depend on Tim-3. On the other hand, galectin-9 induced Tim-3-dependent apoptosis in differentiated Tim-3 positive TH17 cells. The inventors of the present invention found out that CD4 positive T cells includes a cell population expressing galectin-9 on cell surfaces. Hereinafter, a CD4 positive T cell expressing galectin-9 on a cell surface may also be referred to as a “THGAL9 cell”. By subjecting THGAL9 cells to TCR stimulation, it is possible to increase the expression of CD25, and to cause galectin-9 and IL-10 to be secreted thereafter, for example. Treg cells also may secrete IL-10 in some cases. However, THGAL9 cells do not express Foxp3 as a Treg marker. Hence, THGAL9 cells are considered to be different from Treg cells. THGAL9 expressed all the reported IL-10-producing type 1 regulatory T cell (Tr1 cell) markers. However, the expressions of these Tr1 markers are induced in most of CD25 positive CD4 cells by TCR stimulation, so that these Tr1 markers are not decisive Tr1 markers. Interestingly, inside CD4+ T cells other than THGAL9, galectin-9 also is expressed in an amount equivalent to that in THGAL9. When THGAL9 cells are co-cultured with naïve T cells committed to differentiate into TH17 cells, the production of IL-17 is inhibited and Treg cells are increased. These actions are similar to those of recombinant galectin-9. Thus, this strongly suggests that cells that regulate immunity via galectin-9 secretion in vivo are THGAL9 cells. Furthermore, it was found that THGAL9 cells having similar properties are present also in humans. The above-described findings show that cell surface galectin-9 is an excellent Tr1 marker, and also that a THGAL9 cell is a very useful cell that can be applied directly or indirectly to treatment of autoimmune diseases, allergic diseases, tumors, and other diseases.
Moreover, the inventors of the present invention demonstrated that the inhibition of TH17 cell differentiation by the THGAL9 cell is inhibited by a galectin-9 inhibitor but not inhibited by an IL-10 inhibitor or a TGF-β inhibitor, thereby verifying that galectin-9 is a substance chiefly responsible for this inhibitory activity.
Moreover, the inventors of the present invention further discovered that cells similarly expressing galectin-9 on cell surfaces can be found also in: T cells other than CD4 positive T cells; γδT cells; natural killer cells (NK cells); B cells; and the like, thereby achieving the cell of the present invention. The cell of the present invention is a cell containing galectin-9, characterized in that the galectin-9 is expressed on a cell surface as described above, and other configurations are not particularly limited.
The fact that the cell of the present invention expresses galectin-9 on a cell surface is considered to verify that the cell of the present invention is a cell that secretes galectin-9. In other words, it is considered that the expression of galectin-9 on a cell surface is observed in the course of the process where the galectin-9 inside the cell is secreted out of the cell. It is to be noted, however, that this description merely illustrates one possible mechanism, and the cell of the present invention is by no means limited by this description.
The cell of the present invention (THGAL9 cell or the like) is a particularly useful cell that can be applied directly or indirectly to, e.g., treatment of autoimmune diseases, allergic diseases, tumors, and other diseases. For example, the cell of the present invention is useful in regulating immunity to prevent and treat illnesses. Furthermore, for example, the cell of the present invention is useful in the medical field for addressing infectious diseases, immune diseases, and organ transplantation, and also is useful as a reagent to be used in the fields of assays, biotechnology, etc.
In the present invention, “galectin-9” is not limited to natural (wild-type) galectin-9. For example, it may be a galectin-9 variant or the like having substantially equivalent activity to the natural (wild-type) galectin-9. The galectin-9 variant may be, for example, a substance that exhibits an activity to bind specifically to a specific carbohydrate chain (such an activity is owned by carbohydrate chain recognition sites of galectin-9), or an activity analogous thereto (such an activity may encompass a qualitative activity and/or a quantitative activity). Galectin-9 (wild-type galectin-9) has an activity to induce apoptosis of specific cells, for example. In the present invention, the galectin-9 variant may have an apoptosis-inducing activity of the wild-type galectin-9 or an activity analogous thereto. Also, the galectin-9 variant may exhibit an activity corresponding to altered or modified biological activity of galectin-9, which is preferable in some cases. In the present invention, galectin-9 variant may serve as a biologically active reagent having properties equivalent to or superior to the wild-type galectin-9 in the field of clinical tests, the field of analyses, or in the medical or pharmaceutical field.
In the present invention, “galectin-9 variant” is not particularly limited, and may be galectin-9 variant described in Patent Document 1 or the like, for example. More specifically, the galectin-9 variant may be as follows, for example. The galectin-9 variant may be, for example: a protein obtained by modification of the linker peptide or a region in the vicinity thereof in the wild-type galectin-9 or a protein having substantially equivalent activity to the wild-type galectin-9, or a salt thereof a protein having an amino acid sequence obtained by modification of the wild-type galectin-9 or a protein having substantially equivalent activity to the wild-type galectin-9 so as to delete, substitute, or add one or more amino acids in the amino acid sequence of the linker peptide or a region in the vicinity thereof, or a salt thereof, resulting in modified degradation susceptibility of at least the linker peptide as compared with the wild-type galectin-9; a protein having substantially equivalent activity to the wild-type galectin-9 and having a homology of at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% to the amino acid sequence of the wild-type galectin-9, or a salt thereof; or a protein obtained by binding (1) the N-terminal carbohydrate recognition domain (NCRD) of the wild-type galectin-9 or a polypeptide having substantially equivalent activity to the NCRD to (2) the C-terminal carbohydrate recognition domain region (CCRD) of the wild-type galectin-9 or a polypeptide having substantially equivalent activity to the CCRD via (3) a modified linker peptide having an amino acid sequence obtained by deletion, substitution, or addition of one or more amino acids in the amino acid sequence of the linker peptide of the wild-type galectin-9, or a salt thereof.
In preferable aspects, the galectin-9 variant may be the one composed of the following (1), (2), and (3), for example: (1) a polypeptide having the following amino acid sequence and having a lactose binding ability: the amino acid sequence of the following SEQ ID NO: 7 shown as the NCRD of the wild-type galectin-9; an amino acid sequence obtained by deletion, substitution, or addition of one or more amino acids in the amino acid sequence of SEQ ID NO: 7; or an amino acid sequence with a homology of at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% to the amino acid sequence of SEQ ID NO: 7; (2) a polypeptide having the following amino acid sequence and having a lactose binding ability: the amino acid sequence of the following SEQ ID NO: 8 shown as the CCRD of the wild-type galectin-9; an amino acid sequence obtained by deletion, substitution, or addition of one or more amino acids in the amino acid sequence of SEQ ID NO: 8; or an amino acid sequence with a homology of at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% to the amino acid sequence of SEQ ID NO: 8, and having a lactose binding ability, and (3) a polypeptide having, as a linker region linking the above (1) and (2), the following amino acid sequence, and preferably more stabilized against proteases such as matrix metalloprotease than the native (wild-type) galectin-9: the amino acid sequence of the following SEQ ID NO: 9; or an amino acid sequence obtained by deletion, substitution, or addition of one or more amino acids in the amino acid sequence of SEQ ID NO: 9. The linker region (3) encompasses: deletion analogs having an amino acid sequence obtained by deletion of one or more (e.g., 1 to 2, preferably 3 to 4, more preferably 5 to 6, still more preferably 7 to 8, and particularly preferablyl to 9) amino acid residues in the amino acid sequence of SEQ ID NO: 9; substitution analogs having an amino acid sequence obtained by substitution of one or more (e.g., 1 to 9, preferably 1 to 8, more preferably 1 to 6, still more preferably 1 to 4, and particularly preferably 1 to 2) amino acid residues in the amino acid sequence of SEQ ID NO: 9 with other residues; and addition analogs having an amino acid sequence obtained by addition of one or more (e.g., 1 to 60, preferably 1 to 40, more preferably 1 to 20, more preferably 1 to 10, and particularly preferablyl to 5) amino acid residues to the amino acid sequence of SEQ ID NO: 9 (provided that those amino acid residues are other than those shown in the part of SEQ ID NO: 10 or 11 obtained by deleting the amino acid sequence of SEQ ID NO: 9 therefrom). Typical examples of the linker region (3) include those having amino acid sequences obtained by modifying the amino acid sequence of SEQ ID NO: 9 so as to substitute amino acids therein with HM, RIP, or a sequence consisting of any two amino acids. The substitution, deletion, or insertion of amino acids may be the one causing no great change in physiological or chemical properties of a polypeptide, or in some cases, it may be the one causing preferable change in the same. A substituent of an amino acid in the amino acid sequence can be selected from other amino acids in the class to which the amino acid belongs. For example, non-polar (hydrophobic) amino acids include alanine, phenylalanine, leucine, isoleucine, valine, proline, tryptophan, and methionine; polar (neutral) amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged amino acids (basic amino acids) include arginine, lysine, and histidine; and negatively charged amino acids (acidic amino acids) include aspartic acid and glutamic acid.
Examples of the linker region (3) further include: those having an amino acid sequence obtained by substitution of amino acid residues in the amino acid sequence of SEQ ID NO: 10 or 11 (excluding those in the part corresponding to the amino acid sequence of SEQ ID NO: 9) with HM, RIP, or a sequence consisting of any two amino acids; and those having an amino acid sequence obtained by deletion of, from amino acid residues in the amino acid sequence of SEQ ID NO: 10 or 11 (excluding those in the part corresponding to the amino acid sequence of SEQ ID NO: 9), all the residues but any six amino acids. Examples of the linker region (3) further include: deletion analogs having an amino acid sequence obtained by deletion of one or more (e.g., 1 to 5, preferably 3 to 10, more preferably 5 to 15, still more preferably 7 to 20, and particularly preferably 1 to 32) amino acid residues from the amino acid sequence of SEQ ID NO: 10 or 11 (e.g., excluding those in the part corresponding to the amino acid sequence of SEQ ID NO: 9, or in the case of SEQ ID NO: 10, those in the part corresponding to the amino acid sequence of SEQ ID NO: 11 may be excluded); substitution analogs having an amino acid sequence obtained by substitution of one or more (e.g., 1 to 9, preferably 1 to 8, more preferably 1 to 6, still more preferably 1 to 4, and particularly preferably 1 to 2) amino acid residues in the amino acid sequence of SEQ ID NO: 10 or 11 with any other residues; and addition analogs having an amino acid sequence obtained by addition of one or more (e.g., 1 to 60, preferably 1 to 40, more preferably 1 to 20, still more preferably 1 to 10, and particularly preferably 1 to 5) amino acid residues to the amino acid sequence of SEQ ID NO: 10 or 11 (provided that those amino acid residues are other than those shown in the part of SEQ ID NO: 10 or 11 obtained by deleting the amino acid sequence of SEQ ID NO: 9 therefrom).
All the mutants described above are encompassed in the present invention, as long as they retain the domain structure or the carbohydrate-binding ability characterizing the natural (wild-type) human galectin-9 protein, for example. Also, it is considered that the peptide or polypeptide of the present invention may encompass those having substantially the same primary structure conformations as the natural human galectin-9 proteins and those having a part of such conformations. Furthermore, it is also considered that the peptide or polypeptide of the present invention may encompass those having substantially equivalent biological activities to the natural human galectin-9 proteins. Furthermore, the peptide or polypeptide of the present invention can be one of naturally-occurring mutants. In the present invention, examples of human-derived proteins (or peptides or polypeptides) include those having an amino acid sequence with a homology higher than 60% or, in some cases, higher than 70%, more preferably at least 80% or 90% to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 3 listed in the Sequence Listing of WO 02/37114 A1. In the present invention, part of a human-derived protein may be any peptide as part of the human-derived protein (i.e., a partial peptide of the protein) as long as it has substantially equivalent activity to the galectin-9 protein of the present invention. Examples of the partial peptide of the protein according to the present invention include those having an amino acid sequence consisting of, among amino acid residues contained in the amino acid sequence constituting human galectin-9, at least 5 amino acid residues, preferably at least 20 amino acid residues, more preferably at least 50 amino acid residues, still more preferably at least 70 amino acid residues, yet more preferably at least 100 amino acid residues, and in some cases, at least 200 amino acid residues. Preferably, these amino acid residues are continuous, or, for example, these amino acid residues have the same homology as described above, with respect to the corresponding region in the amino acid sequence of any one of SEQ ID NOs: 1 to 3 in the Sequence Listing of WO 02/37114 A1.
In the present invention, when a galectin-9 variant has “substantially equivalent” activity to the wild-type (natural) galectin-9, it means, for example, that the galectin-9 variant retains the carbohydrate recognizing activity of the natural galectin-9. From a different viewpoint, when the galectin-9 variant has “substantially equivalent” activity to the wild-type (natural) galectin-9, it means, for example, that they have substantially the same protein activities, which more specifically means, e.g., predetermined cytotoxic activity, apoptosis-inducing activity, anti-inflammatory activity, anti-allergic activity, immunomodulating activity, carbohydrate chain binding activity, physiological activity, and biological activity. Furthermore, the meaning of the term also may encompass the case where they have activities of substantially the same quality, examples of which include binding activity, cytotoxic activity, and apoptosis-inducing activity. When activities have substantially the same quality, it means that these activities are qualitatively homogeneous, which means, for example, physiologically, pharmacologically, or biologically homogeneous. For instance, it is preferable that the activities such as the binding activity, cytotoxic activity, and apoptosis-inducing activity are equivalent (e.g., about 0.001- to about 1000-fold, preferably about 0.01- to about 100-fold, more preferably about 0.1-to about 20-fold, and still more preferably about 0.5- to about 2-fold), but quantitative factors such as the extents of these activities, molecular weights of the proteins, etc. may be different.
Other objects, features, advantages, and aspects of the present invention would be apparent to those skilled in the art from the following descriptions. It should be understood, however, that the following descriptions and descriptions in other parts of the specification including specific examples etc. are directed to preferred embodiments of the present invention and given merely for illustrative purposes. Those skilled in the art would easily understand that various changes and/or alterations (or modifications) of the present invention may be made without departing from the spirit and scope of the present invention as disclosed herein, based on knowledge from the following descriptions and other parts of the specification. All of the patent documents and reference documents listed herein are cited for illustrative purposes, and the entire disclosures thereof should be interpreted as being incorporated herein by reference.
In the present invention, a CD4 positive T cell that expresses galectin-9 on a cell surface was discovered together with the fact that this cell secretes galectin-9 to control the balance between TH17 cells and Treg, and the cell was named “THGAL9 cell”. It was found that the THGAL9 cell produces IL-10 and expresses Latency-associated peptide (LAP), NKG2D, lymphocyte activation gene-3 (LAG-3), and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) on a cell surface. This suggests the possibility that the THGAL9 cell may be the same as a Foxp3 negative inhibitory T cell, i.e., a Tr1 cell (Non-Patent Documents 20 to 22) or belong to a subpopulation thereof.
Tr1 cells play an important role in immunological tolerance induced by plasmacytoid dendritic cells (Non-Patent Documents 20, 23 to 25, 15 to 18). In vitro, they are induced by subjecting naïve CD4+ T cells to TCR stimulation in the presence of IL-27 or Vitamin D3/dexamethasone (Non-Patent Documents 26 to 29). Although the above-described LAP, NKG2D, LAG-3, and CTLA-4 are known as cell surface markers of the Tr1 cells, they are also expressed by CD4+CD25+ cells, which do not produce IL-10. Thus, a reliable Tr1 cell marker would be highly expressed inhibitory cytokine IL-10, which is considered to be chiefly responsible to the function of the Tr1 cell. However, the production of IL-10 can be seen not only in Tr1 cells but also in other cell groups including Treg cells, so that IL-10 cannot serve as a decisive Tr1 marker (Non-Patent Documents 30 to 31). Moreover, at present, no techniques are available that allows cells to be purified alive in a simple manner using the expression of IL-10 present inside the cells as an indicator. These facts render the Tr1 research and application thereof difficult.
In the present invention, as described above, immune cells expressing galectin-9 on cell surfaces, other than THGAL9, also were discovered. The possibility also is suggested that not only THGAL9 cells but also these cell groups can be used as surrogate markers in diagnosis, or can be applied to cell therapy after being purified using cell surface galectin-9.
The present invention provides cells that secretes galectin-9, as well as techniques applying the same. For example, the present invention provides type 1 T regulatory cells that secrete Gal-9 and IL-10, as well as techniques applying the same. The present invention provides techniques for identifying novel T cells (THGAL9 cells) that can secrete galectin-9 and making these cells available. The present invention also provides techniques for controlling the differentiation into TH17 cells and Treg cells utilizing THGAL9 cells. The THGAL9 cells express not only galectin-9 on cell surfaces but also known Tr1 cell markers, and can secret IL-10, for example. The present invention also provides a technique for purifying Tr1 cells using galectin-9 as a Tr1 cell marker and also applying the thus-purified Tr1 cells to treatment. The present invention also provides a technique for inducing the increase in CD25 expression and secretion of galectin-9 and IL-10 by subjecting THGAL9 cells to TCR stimulation. The present invention also provides a technique for inhibiting the production of IL-17 and/or increasing Treg cells by co-culturing THGAL9 cells with naïve T cells committed to differentiate into TH17 cells. The present invention also provides a technique for regulating immunity in vivo using THGAL9 cells. The present invention also provides a cell sorting technique for sorting out regulatory immune cells using cell surface galectin-9 as a marker, and a Tr1 cell sorting technique for sorting out IL-10-producing type 1 regulatory T cells (Tr1 cells) using cell surface galectin-9 as a marker.
The cells discovered in the present invention, e.g., a THGAL9 cell, are useful in the field of clinical tests as a reagent having biological activity, such as a diagnostic agent or a therapeutic agent, in the field of analysis, or in the medical or pharmaceutical field.
The method for separating (or isolating) the cells of the present invention (e.g., THGAL9 cells) from a tissue of a living organism (animal) is not particularly limited, and those skilled in the art can carry out the method without undue experimentation based on the descriptions in the specification and drawings of the present application, and common general technical knowledge at the time of filing the present application. For example, the method for separating (or isolating) the cells of the present invention (e.g., THGAL9 cell) from a tissue of a living organism (animal) may be a method for separating (or isolating) the cells by staining them with an anti-galectin-9 antibody and then separating (or isolating) the stained cells by sorting, as described in the following examples.
Also, the method for producing the cells of the present invention (e.g., THGAL9 cells) is not particularly limited, and may be, for example, a method for separating (or isolating) the cells of the present invention from an animal tissue in which the cells of the present invention already are present. In addition to or instead of this, the cell production method of the present invention may include the step of causing cells not expressing galectin-9 to express galectin-9 on cell surfaces, thus transforming the cells to the cells according to the present invention. This step can be performed in vivo or in vitro, for example. The method for performing this step in vivo may be, for example, as in the first production method of the present invention, administering galectin-9 to an animal, thus inducing expression of galectin-9 on cell surfaces of at least part of cells of the animal. The method for performing this step in vitro may be, for example, as in the second production method of the present invention, culturing one or more cells of an animal in the presence of galectin-9, thus inducing galectin-9 expression on a cell surface of at least one of the cells. The second production method of the present invention may be configured so that, for example, the cells of the animal include at least one cell expressing galectin-9 on a cell surface, and by culturing the cells in the presence of galectin-9, the proportion of the cell expressing galectin-9 on the cell surface is increased.
The term “diagnostic agent” as used herein refers to any agent that contributes to one or more diagnostic actions used in diagnostic applications of the present invention. These diagnostic applications may include a method for determining the presence of galectin-9-producing cells or a method for determining the presence of cells providing a galectin-9-binding substance. The diagnostic agent may be, for example, any agent that contains one selected from the group consisting of cells expressing galectin-9 on cell surfaces and homogenates of the cells.
The term “therapeutic agent” as used herein may refer to any agent that accomplishes or contributes to the accomplishment of one or more therapeutic actions used in therapeutic applications of the present invention. For example, in the case where a therapeutic agent is a cell expressing galectin-9 on a cell surface or a homogenate of the cell, the therapeutic agent can be administered to a mammal. The therapeutic agent may be the one that achieves its therapeutic purpose alone or in combination with any other agent (e.g., an agent to be used together with administration of galectin-9 variant and is applicable to other known treatments for, e.g., a particular tumor or autoimmunity; or a gene delivery vehicle that can cause galectin-9 expression easily in a mammal). For example, the therapeutic agents may contain a galectin-9 variant developed for other purposes, and may further contain an agonist of galectin-9 or an agent that modify or modulate the activities of galectin-9. The therapeutic agents can be, for example, a low molecular weight organic compound or substance, a peptide, a peptide-like compound or substance, a polynucleotide coding for a galectin-9 variant polypeptide, a galectin-9 variant polypeptide, or a transformed cell expressing a chimera or mutant of galectin-9 variant that is stabilized toward protease more than the native galectin-9.
The term “patient” as used herein may refer to any living organism to which any treatment or preventive care can be applied. Examples of the patient include, but not limited to, eukaryotes. For example, an eukaryote as a patient may be a vertebrate. Thus, for example, the patient preferably is a mammal. The mammal can be a human, for example.
General methods for production and use of the therapeutic agent and/or diagnostic agent according to the present invention will be described below. In one aspect, the present invention provides a technique for treating diseases, illnesses, and abnormal conditions caused by the deficiency or absence of physiological or biological activity owned by galectin-9. The treatment technique includes, for example, the step of providing a therapeutic agent containing the cells of the present invention (e.g., THGAL9 cells or the like) and/or the step of administering an effective amount of therapeutic agent containing the cells of the present invention (e.g., THGAL9 cells or the like) to a mammal having any of the above described diseases etc. The cell of the present invention (e.g., THGAL9 cell or the like) may be used so as to exhibit: cytotoxic activity against malignant tumor cells; apoptosis-inducing activity against malignant tumor cells; anti-tumor activity (anti-cancer activity) against malignant tumor cells; apoptosis-inducing activity against activated T cells, especially against CD4 positive T cells; immunomodulating activity; anti-inflammatory action; and anti-allergic action. Thus, it is expected that the cell of the present invention can be useful as an anti-tumor agent (anti-cancer agent), an anti-allergic agent, an immunomodulatory agent, an anti-autoimmune disease agent, an anti-inflammatory agent, and an alternate agent for adrenocortical steroid hormones.
The above-described treatment technique encompasses a method for treating an autoimmune disease characterized by a large amount of activated T-cells. The terms “autoimmune disease” and “autoimmunity” both refer to a disorder characterized by autoimmunity in mammals (a response of an immune system against self-components). An autoimmune response can develop into symptoms showing clinical signs. Strictly speaking, transplantation rejection is not an autoimmunoreaction. However, when a patient has surgery to replace or graft cells, tissue, or an organ to treat his symptoms, the body undergoing allogeneic transplantation can react immunologically against a foreign graft. “Transplantation rejection” occurs if, during allogeneic transplantation of cells, tissue, or an organ from one member of a species to another, the receptor (recipient) causes an immune response sufficient to reject the transplanted cells, tissue, or organ.
Examples of “tumor” that can be treated by the method and therapeutic agent according to the present invention may include malignant tumors. For example, tumors that may metastasize are malignant tumors. Generally, there are two main categories of malignant tumors, namely, epithelial malignant tumors and non-epithelial malignant tumors. In some cases, malignant tumors may be classified into cancers, sarcoma, leukemia, etc. However, when ordinary people simply say “cancers”, it refers to malignant tumors in most cases. The term “cancers” as used herein may be interpreted broadly, and should not be interpreted as merely referring to epithelial malignant tumors. The term “cancers” as used herein may encompass epithelial malignant tumors and non-epithelial malignant tumors (including those that are tumorigenic and non-tumorigenic tumorigenic). Examples of the cancers include skin cancers (which may include melanomas), breast cancers, ovarian cancers, uterine cancers, malignant testicular tumors, prostate cancers, bladder cancers, kidney cancers, thyroid cancers, pharyngeal and laryngeal cancers, tongue cancers, maxillary cancers, esophageal cancers, stomach cancers, colon and rectal cancers, lung and bronchial cancers, liver cancers (including hepatocellular cancers and intrahepatic bile duct cancers), extrahepatic bile duct and gallbladder cancers, pancreatic cancers, leukemia, malignant lymphoma, plasmacytoma, osteosarcoma, chondrosarcoma, leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, malignant hemangioma, malignant hemangioendothelioma, and brain tumors (including meningioma, glioma, astrocytoma, etc.). It should be understood, however, that examples of the cancers are not limited thereto, and also may encompass cancers for which any favorable result can be obtained by the use of the cell of the present invention (e.g., THGAL9 cell or the like), and further, cancers which yield any physiological or biological response when the cell of the present invention (e.g., THGAL9 cell or the like) is involved therein.
Examples of the “autoimmune diseases” that can be treated by the method and therapeutic agent according to the present invention include multiple sclerosis, Hashimoto's thyroiditis, systemic lupus erythematosus (SLE), Goodpasture's syndrome, pemphigus, receptor autoimmunity, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, osteoarthritis, chronic rheumatoid arthritis, scleroderma with anticollagen antibodies involved, mixed connective tissue diseases, polymyositis, pernicious anemia, idiopathic Addison's disease, spontaneous infertility, glomerulonephritis, bullous pemphigoid, adrenergic drug resistance, chronic active hepatitis, primary biliary cirrhosis, autoimmune-based endocrine gland failure, vitiligo, vasculitis, post-myocardial infarction, post-cardiotomy syndrome, urticaria, atopic dermatitis, autoimmune-based asthma, autoimmune-based inflammatory reactions, granulomatous disorders, ankylosing spondylitis, post-streptococcal glomerulonephritis, autoimmune hemolytic anemia, encephalitis, autoimmunoreactions secondary to lymphoma, degenerative disorders, and atrophic disorders. Examples of autoimmune diseases involving autoimmunity against receptors include Graves' disease, myasthenia gravis, and insulin resistance. Examples of autoimmune diseases involving adrenergic drug resistance include asthma and cystic fibrosis.
Other autoimmune diseases to which the present invention is applicable include those for which animal models exist. Examples of such autoimmune diseases include Sjögren's syndrome (autoimmune dacryoadenitis or immune-mediated sialadenitis), autoimmune myocarditis, primary biliary cirrhosis (PBC), inflammatory heart diseases, mercury-induced renal autoimmunity, insulin-dependent diabetes (type I diabetes or IDD), post-thymectomy autoimmunity, central nervous system (CNS) demyelination disorders, CNS lupus, narcolepsy, immune-mediated PNS disorders, osteoarthritis, chronic rheumatoid arthritis, uveitis, medullary cystic fibrosis, autoimmune hemolytic diseases, autoimmune vasculitis, ovarian autoimmune diseases, and scleroderma. Examples of autoimmune diseases characterized by central nervous system (CNS) demyelination disorders include multiple sclerosis (MS). A peripheral nervous system (PNS) autoimmune disease may be Guillain-Barre syndrome (GBS), for example.
The present invention discloses a method for treating a mammal afflicted with a disease or illness selected from: tumors including malignant tumors such as cancers; allergic diseases; inflammations; immune abnormality; and autoimmune diseases including activated lymphocytes (in particular, activated T cells, and the activated lymphocytes may include activated B cells) by administrating a therapeutic agent containing at least one selected from the group consisting of the cells of the present invention (e.g., THGAL9 cells and the like); homogenates of the cells; and extracts of the cells (e.g., the therapeutic agent may be a composition containing, as a therapeutically active ingredient: the cell of the present invention (e.g., THGAL9 cell or the like); or a stimulating agent for stimulating the cell). Autoimmune diseases that can be treated by the method and composition of the present invention include any autoimmune diseases and transplantation rejections (e.g., including, but not limited to, those autoimmune diseases listed herein).
When the present invention is used to obtain cytotoxic actions on tumor cells including malignant tumor cells such as cancer cells, to obtain anti-allergic actions, to obtain anti-inflammatory actions, to normalize immune abnormality, or to induce apoptosis of activated lymphocytes (which may include activated T cells, in particular), the present invention should be interpreted in the same way as in the case of the above-described autoimmunity.
A substance containing at least one selected from the group consisting of the cells of the present invention (e.g., THGAL9 cells and the like); homogenates of the cells; and extracts of the cells has high potential to serve as an anti-tumor agent, an anti-allergic agent, an immunomodulatory agent, an anti-autoimmune disease agent, an anti-inflammatory agent, and an agent utilizing an activity similar to that of adrenocortical steroid hormone, and is considered to exhibit biological activity useful for the following pathological symptoms and diseases.
Inflammatory diseases include a variety of acute and chronic inflammations occurring in various organs, allergic and autoimmune inflammations, and infectious diseases.
Examples of the acute and chronic diseases include a wide variety of inflammations. Specifically, examples of inflammations in the lungs include bronchitis, bronchopneumonia, interstitial pneumonia, pneumonitis, bronchiolitis, and acute mediastinitis. Examples of inflammations in other organs include pericarditis, endocarditis, myocarditis, stomatitis, angular stomatitis, tonsillitis, pharyngitis, laryngitis, esophagitis, peritonitis, acute gastritis, chronic gastritis, acute enteritis, appendicitis, ischemic colitis, drug-induced colitis, proctitis, various acute and chronic hepatitis (such as hepatitis A, hepatitis B, hepatitis C, fulminant hepatitis, and chronic hepatitis), cirrhosis, cholecystitis, acute and chronic pancreatitis, acute and chronic nephritis, membranous glomerulonephritis, glomerulonephritis, IgA nephropathy, a variety of cystitis, encephalomyelitis, mastitis, dermatitis, superficial keratitis, xerotic keratitis, a variety of otitis media and rhinitis, sinusitis, nasal polyp, gingivitis, periodontitis, and paradentitis.
Also, a substance containing at least one selected from the group consisting of: the cells of the present invention (e.g., THGAL9 cells and the like); homogenates of the cells; and extracts of the cells can be effective for, for example, neurogenic inflammation (e.g., neurogenic gastritis, neurogenic cystitis, and the like). For instance, it has been verified that galectin-9 strongly inhibits inflammatory responses in capsaicin-induced neurogenic skin inflammation models. Capsaicin is a substance that stimulates peripheral nerves, thereby causing neurogenic inflammation and pain.
Capsaicin stimulates the release of substance P, which is a neuropeptide stored by sensory C fiber endings. Substance P induces release of histamine from mast cells, thereby causing vasodilatation, which may result in edema. Sensory nerves are stimulated by the released histamine. As a result, an enhancement cycle is established in which substance P is released from C fiber endings and acts on surrounding mast cells, thereby causing more histamine to be released. Galectins exert inhibitory actions on this pathogenic process.
Further, capsaicin binds to a capsaicin receptor (vanilloid receptor) as a pain sensor in sensory nerve endings, thus causing pain. Pain is caused by activation of sensory nerve endings with chemical stimulation (by acid or the like), thermal stimulation (by hot water or the like), or excessive mechanical stimulation (by a blow or the like). The capsaicin receptor also is involved in pain caused by such stimulation. Therefore, it is suggested that galectin-9 may inhibit capsaicin receptor-mediated activation of nerve endings. Thus, galectin-9 has much promise in analgesic applications including relief of pain associated with cancers and inflammations.
Examples of the allergic inflammatory diseases include systemic anaphylaxis, bronchial asthma, hypersensitivity pneumonitis, pollinosis, allergic rhinitis, allergic conjunctivitis, immune complex-induced allergic diseases, and angioneurotic edema.
Examples of the autoimmune inflammations (autoimmune diseases) include: systemic diseases (chronic rheumatoid arthritis, systemic lupus erythematosus, polyarteritis nodosa, scleroderma, polymyositis and dermatomyositis, Sjögren's syndrome, Behcet's disease, and the like); nervous system diseases (multiple sclerosis, myasthenia gravis, HAM (HTLV-1 myelopathy), amyotrophic lateral sclerosis, and the like); endocrine diseases (Basedow's disease, Hashimoto's disease, type 1 diabetes, and the like); blood diseases (idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, aplastic anemia, and the like); respiratory diseases (sarcoidosis, pulmonary fibrosis, and the like); gastrointestinal diseases (ulcerative colitis, Crohn's disease, and the like); hepatic diseases (autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune cholangitis, and the like); and renal and urinary system diseases (anti-neutrophil cytoplasmic antibody associated nephritis, vasculitis, Goodpasture's syndrome, anti-glomerular basement membrane antibody disease, and the like).
Infectious diseases collectively refer to diseases resulting from damage to cells, tissue, and organs of living organisms by pathogens. Regarding infectious diseases, the following book can be referred to: Supervisor: Rikuo MACHINAMI, Editor: Junichi HATA & Atsuhiko SAKAMOTO, “Hyoujun Byourigaku, 2nd Edition”, Igaku-Shoin Ltd., published on Mar. 15, 2002. Pathogens that cause infectious diseases in human include: 1) bacteria (including spirochetes, chlamydiae, and rickettsiae); 2) viruses; 3) fungi; 4) plants (algae); 5) protozoa; 6) parasites (trematodes, cestodes, nematodes); and 7) arthropods. Major diseases caused by the respective pathogens include: bacterial infections (cholera, pest, Escherichia coli infection, and the like); spirochete infections (leptospirosis, and the like); chlamydial infections (psittacosis, and the like); rickettsial infections (epidemic typhus, tetanus, and the like); viral infections (zoster, viral hemorrhagic fever, rabies, and the like); fungal infections (candidiasis, cryptococcosis, aspergillosis, and the like); protozoan infections (amebic dysentery, malaria, toxoplasmosis, and the like); parasitic infections (trematodiasis, nematodiasis, and the like); and other infectious diseases such as mycoplasma infections (mycoplasma pneumonia and the like) and mycobacterial infections (tuberculosis, atypical mycobacterial infection, and the like).
Sarcomas and cancers include brain tumors (glioblastoma multiforme and the like), spinal cord tumors, maxillary sinus cancer, pancreatic ductal adenocarcinoma, gingival cancers, tongue cancers, lip cancers, nasopharyngeal cancers, oropharyngeal cancers, hypopharyngeal cancers, laryngeal cancers, thyroid cancers, parathyroid cancers, lung cancers, pleural tumors, carcinomatous peritonitis, carcinomatous pleurisy, esophageal cancers, stomach cancers, large bowel cancers, bile duct cancers, gallbladder cancers, pancreatic cancers, liver cancers, kidney cancers, bladder cancers, prostate cancers, penile cancers, testicular tumors, adrenal cancers, cervical cancers, endometrial cancers, vaginal cancers, vulvar cancers, ovarian cancers, chorioepithelioma, malignant bone tumors, soft tissue sarcomas, breast cancers, skin cancers, malignant melanoma, basal cell tumors, leukemia, myelofibrosis involving myeloid metaplasia, malignant lymphoma, Hodgkin's disease, plasmacytoma, and glioma.
According to the present invention, for example, as described above, it is possible to diagnose a disease of an animal or a symptom caused by the disease by detecting, in a tissue of the animal containing or not containing the cell of the present invention, the cell of the present invention qualitatively or quantitatively by the cell detection method of the present invention. The disease of the animal is not particularly limited, and can be any of the above-described diseases, for example. Furthermore, according to the present invention, for example, as described above, it is possible to determine a therapeutic effect on a disease of an animal by a method including the steps of treating the disease of the animal; diagnosing the disease or a symptom caused by the disease by the diagnostic method of the present invention before and after the treatment; and comparing diagnostic results obtained before and after the treatment. The disease of the animal is not particularly limited, and can be any of the above-described diseases, for example.
EXAMPLESThe present invention will be described specifically below with reference to examples, which are provided in order to present information on specific embodiments of the present invention only for illustrative purposes. These illustrative examples are provided to give explanations on specific embodiments of the present invention, and should not be construed as in any sense limiting or restricting the scope of the invention disclosed herein. It should be understood that, in the present invention, various embodiments can be made or executed within the spirit, scope, and concept disclosed herein.
The following examples can be carried out by those skilled in the art without undue experimentation based on specific descriptions in the respective examples and common general technical knowledge at the time of filing the present application. In the following examples, if a mechanism by which an observed phenomenon occurs is considered, it should be understood that such a mechanism merely is one conceivable example, and does not limit the present invention by any means.
<Materials and Methods Used in Experiments>
In the following, particularly important materials and methods used in experiments will be described.
(Recombinant Galectin-9)Every recombinant galectin 9 used in the examples was stabilized human galectin 9 (G9NC(null)) prepared according to reported methods (Non-Patent Documents 12 and 33, and Patent Document 1). The authentic sample exhibited a purity of at least 95% according to SDS-PAGE and a protein purity test with Coomassie Brilliant Blue staining. The amount of endotoxin contained therein was not more than 0.1 ng per 1 mg of the stabilized human galectin, according to the kinetic turbidimetric Limulus test. The binding affinity of the stabilized human galectin-9 to mouse Tim-3 is equivalent to that of mouse galectin-9. Molar concentrations were calculated assuming a molecular weight of 33065.
The stabilized human galectin-9 (G9NC(null)) preparation method described in Patent Document 1 is as follows.
(A) Construction of Galectin-9 Variant Expression Vector
The expression vector was constructed using the following (1) to (3):
(1) cDNA prepared from a poly(A)+ RNA fraction of Jurkat cells
(2) pET-11a vector (STRATAGENE)
(3) PCR primers:
The Jurkat cells (T cell-derived cells) were obtained from American Type Culture Collection (ATCC). The cell line was maintained in a RPMI-1640 medium (Sigma, St. Louis, USA) containing 10% FCS at 37° C. under 5% CO2. Total RNA extraction from the Jurkat cells was carried out in the following manner. The Jurkat cells cultured in the 10% FBS-containing RPMI-1640 medium were collected by centrifugation, and washed twice with 10 ml of PBS. To the washed cell pellets, ISOGEN (trade name, NIPPON GENE CO., LTD.) was added (15 ml per 2×108 cells). Then, in accordance with the manual (NIPPON GENE CO., LTD.), total RNA was extracted therefrom. Purification of poly(A)+ RNA from the total RNA and synthesis of cDNA were carried out in the following manner. The total RNA extracted from the Jurkat cells was dissolved in DEPC-treated water at a concentration of 1 mg/ml. poly(A)+ RNA was purified from the total RNA using a PolyA Ttract mRNA Isolation System (trade name, Promega) in accordance with its manual. The purified poly(A)+ RNA was dissolved in DEPC-treated water at a concentration of 5 μg/20 μl. cDNA was synthesized from 5 μg of the poly(A)+ RNA using a First-Strand cDNA Synthesis Kit (trade name, Amersham Biosciences) in accordance with its manual (as a primer, Not I-d(T)18 was used).
Next, the N-terminal carbohydrate recognition domain (NCRD) and the C-terminal carbohydrate recognition domain (CCRD) of galectin-9 were inserted into the NdeI-BamHI site of a pET-11a vector in a manner outlined in the following. Thus, an expression vector for a modified galectin-9 (G9NC(null)) lacking the linker peptide was produced.
First, from the galectin-9 cDNA, the following (1) and (2) were obtained: (1) cDNA corresponding to the C-terminal CRD of human galectin-9; and (2) cDNA corresponding to the N-terminal CRD of human galectin-9. More specifically, the cDNA corresponding to the C-terminal CRD of human galectin-9 (G9CCRD) was amplified from the cDNA using the PCR primers G9CCRD5 and G9CCRD6. G9CCRD was cleaved with restriction enzymes (NdeI+BamHI), and inserted into the pET-11a vector treated with the same restriction enzymes. Thus, pET-G9CCRD was obtained. PCR was conducted using a KOD DNA polymerase kit (TOYOBO Code No. KOD-101). A PCR reaction mixture (dNTP mix, 25 mM MgCl2, 10× Buffer, KOD DNA polymerase (0.05 u), primers, and a template cDNA) was reacted under the following PCR cycle conditions: the reaction mixture was treated at 94° C. for 2 minutes, then was subjected to 25 cycles of treatment (with a treatment at 98° C. for 15 seconds, at 65° C. for 2 seconds, and at 74° C. for 30 seconds as one cycle), and finally, the reaction was terminated at 4° C. The PCR amplified fragment was inserted into the vector using a Ligation high kit (TOYOBO Code No. LGK-101). To cause a reaction, the PCR-amplified fragment was mixed with the vector at a molar ratio of insert:vector=about 5:1, and then the resultant DNA solution was mixed with a reagent “Ligation high”. The amount (volume) of the reagent was 1/2 of the total amount (volume) of the DNA solution. The reaction was allowed to proceed at 16° C. for 16 hours (O/N), thereby achieving insertion.
Also, the cDNA corresponding to the N-terminal CRD of human galectin-9 (G9NCRD) was amplified from the galectin-9 cDNA using PCR primers G9NCRD1 and G9NCRD6. G9NCRD was cleaved with a restriction enzyme (NdeI). Into the pET-G9CCRD that had been treated with the same restriction enzyme (NdeI) and then further dephosphorylated, the resultant fragment was inserted. Thus, pET-G9NC (null) was obtained. The PCR amplification and incorporation into the vector were carried out in the same manner as in the above. The pET-G9NC (null) codes for a polypeptide having an amino acid sequence obtained by substitution of 29 amino acids from Pro-149 to Ser-177 in the amino acid sequence of human M-type galectin-9 with the His-Met sequence. In other words, the pET-G9NC (null) has a base sequence of the following SEQ ID NO: 5, which codes for a polypeptide having an amino acid sequence of the following SEQ ID NO: 6.
(B) Expression and Purification of Galectin-9 Variant Recombinant Protein
The expression plasmid vector pET-G9NC (null) obtained in the above-described process (A) was introduced into E. coli (BL21 (DE3)). The introduction was carried out by electroporation. More specifically, competent BL21 (DE3) was mixed with an aqueous plasmid vector solution, and the resultant mixture was subjected to electroporation at a voltage of 1.8 kV for transfection.
The expression of the recombinant protein was induced by culturing the E. coli in a 2×YT medium containing 2% (w/v) glucose and 100 μg/ml ampicillin, and then adding 0.1 M isopropyl-β-D-thiogalactopyranoside to the medium (final concentration: 0.1 mM) at a time point when the absorbance of the medium at 600 nm reached 0.7. After the E. coli was cultured at 20° C. for 18 hours, the bacterial cells were collected by centrifugation, and then suspend in 10 mM Tris-HCl (pH 7.5) containing 0.5 M NaCl, 1 mM DTT, and 1 mM PMSF. The resultant suspension was subjected to sonication for 10 minutes. Thereafter, 10% (w/v) Triton X-100 was added to the suspension (final concentration: 1%), and the resultant mixture was stirred at 4° C. for 30 minutes. The mixture was centrifuged at 15,000×g for 30 minutes, and the resultant supernatant was subjected to affinity chromatography using lactose-agarose to purify the recombinant protein in the supernatant. Cellufine ET clean L (CHISSO) was used to remove endotoxin, and whether or not the endotoxin had been removed was checked by a kinetic turbidimetric Limulus test using a Toxinometer.
As a result, an authentic sample of the recombinant protein with high purity was obtained with a relatively high yield. The result of electrophoresis of the thus-obtained recombinant protein was shown in
(Antibody)
The following antibodies were used for cell staining: an anti-mouse CD4-FITC antibody (Becton Dickinson or eBioscience, San Diego, Calif.), an anti-mouse Tim-3-PE antibody (eBioscience), an anti-mouse galectin-9-Alexa 488 antibody (clone 108A2, GalPharma), an anti-mouse galectin-9-PE antibody (clone 108A2, Biolegend), an anti-mouse CD25-APC antibody (Biolegend), an anti-mouse Foxp3-APC antibody (eBioscience), anti-human/mouse LAP-PE antibody (R&D Systems), an anti-mouse NKG2D-PE antibody (Biolegend), an anti-mouse LAG-3-PE antibody (Biolegend), an anti-mouse CTLA-4-PE antibody (Biolegend), an anti-mouse IL-17 antibody—(for FACS), an anti-mouse PDCA-1-APC antibody (Biolegend), an anti-mouse CD11c-Alexa 488 antibody (Biolegend), an anti-mouse CD19 antibody (Biolegend), an anti-mouse GL-7 antibody (Biolegend), an anti-mouse CXCR4 antibody (Biolegend), an anti-mouse ICOS-PE antibody (eBiosciences), an anti-mouse CXCR5-APC antibody (BD Pharmingen), an anti-human galectin-9-Alexa 488 antibody (clone 9M1-3, GalPharma), an anti-human CD4-FITC antibody (Biolegend), an anti-human CD4-PE antibody (Biolegend), an anti-human CD25-APC antibody (Biolegend), an anti-human/mouse Foxp3-PE antibody (Biolegend), an anti-mouse IL-10 antibody (Biolegend), an anti-mouse IL-10 neutralizing antibody (R&D Systems), an anti-mouse IL-10R neutralizing antibody (R&D Systems), and an anti-mouse TGF-β neutralizing antibody (R&D Systems).
(Other Reagents)
Apoptosis measurement was carried out using an Annexin V-EGFP Apoptosis Detection kit (Medical & Biological Laboratories, Nagoya, Japan). For staining of intracellular antigens, a BD Cytofix/Cytoperm Kit (Becton Dickinson) was used to immobilize cells and make cell membranes permeable. These kits were used in accordance with instructions for use provided by the manufacturers.
(Flow Cytometry)
Stained cells were measured using a FACS Calibur (Becton Dickinson), and the obtained data was analyzed using FlowJo software (Tree Star, Ashland, Oreg.). A FACS Aria (Becton Dickinson) was used when cell sorting was necessary.
(ELISA)
The concentration of human galectin-9 was quantified according to the reported method (Non-Patent Document 34).
The concentration of mouse galectin-9 was quantified according to the reported method (Non-Patent Document 16), in which the following three points were modified for improvement: (1) the anti-mouse galectin-9 antibody used for coating a plate was changed to clone 108A2 (GalPharma); (2) as the antibody for detection, an anti-mouse galectin-9 polyclonal antibody (GalPharma) labeled with biotin was used; and (3) accompanying the change in the antibody for detection, horseradish peroxidase-labeled streptavidin (Endogen) was used instead of the third antibody to cause a color-developing reaction. This system specifically detects mouse galectin-9, and no reaction is caused even if a measurement sample contains stabilized human galectin-9 at a concentration of 30 nM. Mouse or human IL-17A, mouse TNF-α, mouse IL-12, mouse IFN-γ, and mouse IL-13 were detected using appropriate DuoSets (R&D Systems), respectively; mouse IL-10 was detected using a Mouse IL-10 ELISA MAX Standard (Biolegend); anti-mouse SRBC IgM was detected using a Mouse Anti-SRBC IgM ELISA Kit (Life Diagnostics); a mouse total IgM antibody and a mouse total IgG antibody were detected using a Mouse Total IgM ELISA Kit and a Mouse Total IgG ELISA Kit (both available from Bethyl), respectively; and an anti-dsDNA antibody was detected using a Lbis anti-dsDNA-mouse ELISA KIT (Shibayagi Co., Ltd.). These kits were used in accordance with instructions for use provided by the manufacturers.
(Animals)
C57BL/6J mice and MRL/MpJUmmCrj-1pr/1pr mice were purchased from Charles River Laboratories Japan, Inc. (Yokohama, Japan); and galectin-9 knockout mice and mouse galectin-9 transgenic mice of the same line were purchased from GalPharma (Takamatsu, Japan). Lewis rats (LEW/Ssn) were purchased from Japan SLC, Inc. (Hamamatsu, Japan). The mice used in this research were kept under standard conditions in a day-and-night-rhythm of 12 h light and 12 h dark and with free access to food and water, and they received humane care in accordance with the national law and international guidelines. The study protocol was approved by the Animal Care and Use Committee of Kagawa University.
The method for the experiments will be described below.
<Isolation and Culture of Mouse Naïve T Cells>
CD4+CD62L+ naïve T cells were isolated from spleen cells obtained from 8- to 10-week old male C57BL/6J mice using a CD4+CD62L+ T cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) in accordance with instructions for use provided by the manufacturer. Thus, naïve T cells with a purity of at least 94% were obtained. The thus-obtained naïve T cells were suspended in a RPMI 1640 medium (Sigma-Aldrich, St. Louis, Mo.) containing 10% heat-inactivated fetal bovine serum, penicillin G (10 IU/ml, Sigma-Aldrich), and streptomycin (100 μg/ml, Sigma-Aldrich). The resultant suspension was inoculated into a 96-well plate (Becton Dickinson) coated with an anti-CD3 antibody (1 μg/ml) at a density of 2×105 cells/0.1 ml/well. An anti-CD28 antibody (2 μg/ml, Becton Dickinson) was added to the plate, and thereafter, the naïve T cells were cultured in a CO2 incubator at 37° C. for 72 to 96 hours. For induction of differentiation into TH17 cells, human TGF-β1 (3 ng/ml, R&D systems), mouse IL-2 (5 ng/ml, R&D systems), and mouse IL-6 (20 ng/ml, R&D systems) were added to this system. For induction of differentiation into TH1 cells, mouse IL-12 (10 mg/ml, R&D systems) and anti-IL-4 antibody (10 μg/ml, Becton Dickinson) were added. For induction of differentiation into TH2 cells, mouse IL-4 (20 mg/ml, R&D systems) and anti-IL-12 antibody (10 μg/ml, Becton Dickinson) were added. For Tr1 differentiation, using a 96-well plate coated with an anti-CD3 antibody (10 μg/ml), the naïve T cells were cultured for 3 days in the presence of an anti-CD28 antibody (2 μg/ml) and IL-27 (25 ng/ml). In some of the experiments, the naïve T cells were cultured in the presence of stabilized human galectin-9 (30 nM), lactose (3, 10, or 30 mM), sucrose (3, 10, or 30 mM), an anti-Tim-3 neutralizing antibody (10 μg/ml, eBioscience), or rat IgG2a (10 μg/ml, eBioscience).
<Action of THGAL9 Cells on Differentiation into TH17 Cells>
CD25 negative THGAL9 (CD25−CD4+ T cells expressing galectin-9 on cell surfaces) and non-THGAL9 cells (cell surface galectin-9−/CD25−/CD4+ T cells) were isolated by sorting (cell purity: at least 97%). On the other hand, the naïve T cells were cultured under TH17 differentiation-inducing conditions for 6 hours, thereby committing the naïve T cells to differentiate into TH17. Thereafter, the cultured cells were collected, and mixed with the CD25 negative THGAL9 cells or the non-THGAL9 cells at a mixing ratio of 1:1 (5×104 cells:5×104 cells). Then, they were cultured for 90 hours under TCR stimulation only. For inhibition of the action of galectin-9, 30 mM lactose was added to the system.
<Isolation and Culture of Human CD4 T Cells>
Peripheral-blood mononuclear cells were isolated by overlaying peripheral blood collected from a healthy subject on a gravity separation solution (LYMPHOSEPAR, Nakalai Tesque, Kyoto, Japan) and then subjecting them to centrifugation in accordance with instructions for use provided by the manufacturer. From the thus-obtained peripheral-blood mononuclear cells, CD4 T cells were isolated using a CD4+ T Cell Isolation Kit II (Miltenyi Biotec) in accordance with instructions for use provided by the manufacturer. For TCR stimulation of the CD4+ T cells, the cells were cultured in the same manner as in the case of the mouse naïve T cells.
Specifically, the CD4+ T cells were suspended in a RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum, penicillin G, and streptomycin, and the resultant suspension was inoculated into a 96-well plate coated with an anti-CD3 antibody (1 μg/ml) at a density of 2×105 cells/0.1 ml/well. An anti-CD28 antibody (2 μg/ml, Becton Dickinson) was added to the plate, and thereafter, the CD4+ T cells were cultured for 96 hours.
To separate human THGAL9 cells and human non-TH17 cells from the thus-obtained cultured cells, the cells were stained with an anti-human galectin-9-Alexa 488 antibody (clone 9M1-3, GalPharma), and sorted using a FACS Aria. The cell purity after the sorting was at least 97%. The cells were cultured for another 96 hours under the TCR stimulation before applying them to the experiments. Differentiation of the human CD4+ T cells into TH17 cells was induced by the reported method (Non-Patent Document 35). Briefly, the CD4+ T cells were cultured for 9 days in the presence of human IL-2 (5 ng/ml, R&D systems) in addition to the above-described TCR stimulation, and further, in the presence of human IL-1β (50 ng/ml, R&D systems), the combination of the same IL-1β and IL-6, or the combination of the same IL-1β and mouse IL-23 (50 ng/ml, R&D systems).
<Real-Time RT-PCR>
mRNA was quantified according to the reported real-time RT-PCR, in which the amplified nucleic acid was stained with SYBR Green I and measured using a ABI PRISM 7000 sequence detector (Applied Biosystems, Foster City, Calif.) (Non-Patent Document 36). Primers were purchased from TAKARA BIO INC. (Otsu, Japan). A specific mRNA expression level was represented as the ratio with respect to the internal standard, which is the mRNA expression level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) quantified by the same real-time RT-PCR.
<Statistical Analysis>
For statistical analysis of data, analysis software Prism (Graphpad software) was used. The presence or absence of a statistically-significant difference was determined by the nonparametric two-tailed Mann-Whitney test, the Logrank test, the 2-way ANOVA, etc., and p values of less than 0.05 (p<0.05) were considered significant. All the numerical values show in bar graphs or line graphs indicate the mean±SEM (n>3).
<Experimental Results and Consideration>
<Stabilized Human Galectin-9 Exhibits Long-Lasting Therapeutic Effect on Rat Arthritis><Pharmacokinetics of Stabilized Human Galectin-9 in Subcutaneous Administration>
Thus, the pharmacokinetics of the stabilized galectin-9 in the case of subcutaneous administration was examined. Lewis rats (♀, 6- to 7-week old) were given single subcutaneous administration of the stabilized human galectin-9 at each dose indicated in
Based on the concentrations of the stabilized human galectin-9 in blood, pharmacokinetic analysis was carried out according to the moment analysis method using moment analysis software (provided by Kenji Tabata, Fujisawa Pharmaceutical Co., Ltd., Graduate School and Faculty of Pharmaceutical Sciences, Kyoto University). As a result, as can be seen from
<Galectin-9 is Endogenous Factor that Inhibits EAE>
clinical score 0: no abnormalities
clinical score 1: hypotonicity in tail
clinical score 2: paraparesis of hind paws
clinical score 3: paraplegia of hind paws
clinical score 4: quadriplegia
clinical score 5: nearly dead or dead
(B) Spinal cords of the mice at week 20 after the immunization were stained with hematoxylin-eosin and immunostained with an anti-CD3 antibody. In the spinal cords of the galectin-9 knockout mice (Gal-9−/−, cell infiltration and tissue destruction were more serious as compared with those in the spinal cords of the wild-type mice (WT). Most of the infiltrated cells were CD3 positive, from which it is speculated that they were T cells.
(C) Spleen cells were prepared from the EAE-immunized wild-type mice (WT) and EAE-immunized galectin-9 knockout mice (Gal-9 KO) at week 20 after the immunization, and non-immunized mice (naïve) of the same week old, and stained with CD4, CD25, IL-17, and Foxp3 antibodies. In the galectin-9 knockout mice, CD4+CD25+IL-17+ cells increased significantly as compared to those in the wild-type mice, whereas CD4+CD25+Foxp3+ cells decreased significantly.
(D) Naïve T cells were prepared from spleen cells of the wild-type mice (WT) and the galectin-9 knockout mice (Gal-9 KO). The naïve T cells were inoculated into a 96-well plate (Becton Dickinson) coated with an anti-CD3 antibody at a density of 2×105 cells/0.1 ml/well. An anti-CD28 antibody (2 μg/ml, Becton Dickinson) was added to the plate, and thereafter, the naïve T cells were cultured for 96 hours (No skewed). For induction of differentiation into TH17 cells, human TGF-β1 (3 ng/ml, R&D systems), mouse IL-2 (5 ng/ml, R&D systems), and mouse IL-6 (20 ng/ml, R&D systems) were added to this system, and the cultured cells were cultured for another 96 hours under this condition (TH17 skewed). The concentration of IL-17A in each culture supernatant was quantified by ELISA. As a result, the expression of IL-17A was induced markedly by the TH17 differentiation-inducing stimulation, and the induction level was significantly higher in the galectin-9 knockout mice than in the wild-type mice.
(E) After the culture supernatant had been extracted in the above described step, the amount of IL-10 mRNA in the remaining cells was quantified by the real-time RT-PCR. The expression level of the IL-10 mRNA was represented as the ratio with respect to the internal standard, which was the signal of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) measured by the same real-time RT-PCR. The expression level of the IL-10 mRNA was significantly lower in the galectin-9 knockout mice than in the wild-type mice in both the conditions of “No skewed” and “TH17 skewed”.
(F) Using the system described in the above (A), the onset of EAE was induced in wild-type female C57BL/6J mice. On day 14 and day 16 after the immunization, the stabilized human galectin-9 was administered subcutaneously to the mice at a dose of 0.3 μg/mouse or 3 μg/mouse. To a control group, PBS was administered. Clinical scores were recorded until day 19 after the immunization. Thereafter, the spinal cords of the mice were stained with hematoxylin-eosin. The stabilized human galectin-9 exhibited a tendency of decreasing the clinical score when it was administered at a dose of 0.3 μg/mouse, and provided statistically significant decrease in the clinical score when it was administered at a dose of 3 μg/mouse (P<0.05, the 2-way ANOVA).
In the galectin-9 knockout mice, symptoms of the experimental allergic encephalitis (EAE) induced with the MOG (33-55) were more serious and lasted longer than in the wild-type mice (
These results demonstrate that galectin-9 adjusts the Th17/Treg balance as an endogenous immunoregulatory factor. Thus, the consequence derived from the previously reported experimental results regarding mouse arthritis (Non-Patent Document 7) was further verified and confirmed in EAE.
<Inhibition of TH17 Cell Differentiation by Galectin-9 does not Depend on Tim3>
(A) CD4+CD62L+ naïve T cells prepared from C57BL/6J mice according to the method described with reference to
(B) In the cells cultured in the presence of the above-described 30 nM stabilized human galectin-9 during the first 24 hours from the start of the TH17 cell differentiation induction and the cells cultured in the presence of the PBS as a control, the mRNA expressions of IL-17F, IL-21, IL-22, and IL23R were quantified by the real-time RT-PCR. The mRNA expressions of all of them were significantly decreased by the stabilized human galectin-9.
(C) The naïve T cells were cultured for 24 hours under the TH17 differentiation-inducing stimulation (TH17 skewed), and CD4+Tim-3+ cells were measured by flow cytometry. As a control, the naïve T cells were cultured for 24 hours under the condition excluding TGF-β1 and IL-6 from the above-described differentiation inducing-stimulation (No skewed). In either case, the expression of Tim-3 cells was almost undetectable. A test regarding inhibition of TH17 differentiation induction by the stabilized human galectin-9 was carried out under the above-described condition (
(D) The naïve T cells were cultured for 96 hours under the TH17 differentiation-inducing stimulation. Thereafter, the stabilized human galectin-9 (30 nM) was added to a cell population containing differentiated TH17 cells. 4 hours later, Tim-3 positive cells, i.e., TH17 cells, having undergone apoptosis were detected by flow cytometry. Also, the same experiment was carried out under the condition where an anti-Tim-3 antibody (10 μg/ml, aTim-3) or an isotype control antibody (10 μg/ml, IgG2a) was added together with the stabilized human galectin-9. The stabilized human galectin-9 induced apoptosis of the TH17 cells, and the effect thereof was significantly inhibited by the anti-Tim-3 antibody. This result suggests that galectin-9 induces apoptosis of differentiated TH17 cells in a Tim-3-dependent manner.
IL-17 production is induced strongly when the naïve T cells were cultured for 4 days in a plate coated with an anti-CD3 antibody under the stimulation with an anti-CD28 antibody, IL-2, TGF-β1, and IL-6. The addition of 30 nM galectin-9 to this TH17 differentiation inducing-system revealed that: when the galectin-9 treatment was performed within 18 hours from the start of the differentiation, the IL-17 production was inhibited markedly; and when the galectin-9 treatment was performed within the first 24 hours from the start of the differentiation, the IL-17 production inhibitory effect obtained was equivalent to that obtained when the galectin-9 treatment was performed throughout the 4 days (
<O-Linked Carbohydrate Chain is Involved in Inhibition of TH17 Differentiation Induction by Galectin-9>
(A) Naïve T cells were cultured under TH17 differentiation-inducing stimulation, and stabilized human galectin-9 (30 nM) or PBS as a control was added within the first 24 hours. During the first 24 hours, lactose (an inhibitor of galectin) was added at a concentration of 3 mM, 10 mM, or 30 mM, and 96 hours later, and the concentration of IL-17A in the culture supernatant was quantified. As a control of the lactose, sucrose, which does not act on galectin-9, was used. The inhibitory action of the stabilized human galectin-9 was eliminated by the lactose in a concentration-dependent manner. This demonstrates that the lectin activity of stabilized human galectin-9 is necessary for inhibition of TH17 differentiation.
(B) Under the same conditions as described in the above (A), swainsonine (2 μg/ml) as an N-glycosylation inhibitor or Benzyl
N-acetyl-α-D-galactosaminide (Benzyl-α-GalNAc, 2 mM) as an O-glycosylation inhibitor was added instead of the lactose. 96 hours later, the concentration of IL-17A in the culture supernatant was quantified. As a result, in the case where the swainsonine was added, the effect of the stabilized human galectin-9 remained significantly, but in the case where the Benzyl-aαGalNAc was used, the significant difference in the effect of the stabilized human galectin-9 was no longer observed. This result implies that a glycoprotein having undergone O-glycosylation is involved in the TH17 differentiation inhibition by galectin-9.
Inhibition of TH17 cell differentiation by galectin-9 was examined in the presence of lactose, which is a low-molecular ligand of galectin-9. As a result, the TH17 differentiation inhibitory effect of the galectin-9 decreased in a manner dependent on the concentration of the lactose added, whereas sucrose, which does not bind to galectin-9, had no effect on this inhibitory effect (
<Action of Galectin-9 on Differentiation into TH1, TH2, and TH17 Cells>
(A) 30 nM stabilized human galectin-9 (or PBS as a control) was added to naïve T cells. The naïve T cells were cultured for 96 hours under stimulation inducing differentiation into each of TH1, TH2, or TH17, or under only TCR stimulation by an anti-CD3 antibody and an anti-CD28 antibody (No skewed). Thereafter, the expression of mRNA specific to each TH subtype was quantified by the real-time RT-PCR. The stabilized human galectin-9 did not give any effect on the expressions of the mRNAs specific to TH1 and TH2 cells, whereas it significantly inhibited mRNA expressions of IL-17A and RORγt specific to TH17 cells only.
(B) mRNAs of IFN-γ and IL-4 under the TH17 differentiation-inducing conditions in the above-described experiment were measured, which revealed that the expressions of both the IFN-γ and IL-4 mRNAs were not changed by the stabilized human galectin-9. Although it is known that TH17 differentiation is inhibited by these cytokines, the above result suggests that the effect of galectin-9 is not for increasing the expressions of these cytokines.
It was found that the inhibition of helper T-cell differentiation by galectin-9 is specific to TH17 cells, and is ineffective against TH1 cell differentiation by IL-12 and against TH2 cell differentiation by IL-4. Also, regarding the expressions of transcription factors specific to the differentiation of each of TH1, TH2, and TH17, galectin-9 could inhibit only the transcription factor RORy of TH17 (
<Galectin-9 Inhibits IL-17 Production in IL-2 Dependent Manner and Enhances Expressions of CD25 and Foxp3>
(A) 30 nM stabilized human galectin-9 (or PBS as a control) was added to naïve T cells, which were then cultured for 24 hours under the TH17 differentiation-inducing condition. By the addition of the stabilized human galectin-9, the proportion of CD4+CD25+ cells was increased significantly. This also was reflected in the increase in mRNA of CD25.
(B) After the naïve T cells were cultured for 96 hours under the condition described in the above (A), the proportion of CD4+CD25+Foxp3+ cells was examined. As a result, the proportion of the CD4+CD25+Foxp3+ cells was increased significantly by the addition of the stabilized galectin-9.
(C) 30 nM stabilized human galectin-9 (control: PBS) and IL-2 at each concentration indicated in
(D) The proportion of Treg cells in the cells cultured for 96 hours under the condition described in the above (C) was measured. The stabilized galectin-9 increased CD4+CD25+Foxp3+ cells, i.e., Treg cells, only in when IL-2 was added.
(E) 30 nM stabilized human galectin-9 (control: PBS) was added to naïve T cells, which were then cultured for 96 hours under the TH17 differentiation-inducing condition. Thereafter, they were cultured for another 6 hours in the presence of PMA (50 ng/ml), ionomycin (1 μg/ml), and brefeldin A (10 μg/ml). The proportions of IL-17+Foxp3− cells and IL-17−Foxp3+ cells in the CD4 positive cells were measured by flow cytometry.
As a result, the galectin-9 induced decrease in IL-17+Foxp3− cells and increase in IL-17-Foxp3+ cells.
(F) Naïve T cells were cultured under the condition described in the above (E), and mRNA expressions of CD25 and Foxp3 at each time point indicated in
The galectin-9 increased the CD4+CD25+ cells and the mRNA level of CD25 under the TH17 cell differentiation-inducing condition (
<Identification of Cell Surface Gal-9 Positive Cells>
(A) Naïve T cells were cultured for 96 hours under the respective conditions described above in connection with
(B) The system for inducing the differentiation of the naïve T cells into TH17 contained IL-2, TGF-β1, and IL-6, in addition to TCR stimulation. This complete system (TH17 skewed) was modified as follows, and naïve T cells were cultured for 96 hours under each of the following conditions: the condition excluding IL-6 from the complete system (TGF-β1 alone); the condition excluding TGF-β1 from the complete system (IL-6 alone), and TCR stimulation only (No skewed). Thereafter, the galectin-9 contained in each supernatant was quantified by ELISA. By the addition of IL-6, the concentration of the galectin-9 was decreased markedly. On the other hand, TGF-β1 added to the system also exhibited a tendency of decreasing the concentration of the galectin-9, but did not provide any significant difference.
(C) 30 nM stabilized human galectin-9 (or PBS as a control) was added to naïve T cells, which were then cultured for 96 hours under each of the following conditions: without stimulation (No stim); TCR stimulation only (No skewed); and TH17 differentiation-inducing stimulation. Thereafter, the galectin-9 in the supernatant was quantified by ELISA. This ELISA was specific to mouse galectin-9, and was not interfere with the 30 nM stabilized human galectin-9 added. The stabilized human galectin-9 increased galectin-9 secretion from the naïve T cells cultured under these conditions.
(D) Using the cells described in the above (C), the amount of galectin-9 mRNA was quantified by the real-time RT-PCR. As a result, no statistically-significant difference was observed among the cells cultured under the respective conditions shown in
(E) On the other hand, the cell surface galectin-9 and CD25 in the cells described in the above (A) were stained, and measured by flow cytometry. As a result, the proportion of the cells expressing galectin-9 on cell surfaces was a little less than 2% of the CD4 positive cells under the unstimulated condition, and increased to about 4% under the TH1, TH2 differentiation inducing-stimulation or TCR stimulation. In contrast, the proportion of the same remained a little less than 2% under the TH17 differentiation-inducing condition. The proportion of the cell surface galectin-9 positive cells under the respective differentiation stimulations agreed well with the secretion of galectin-9.
(F) The above-described cells were sorted into cell surface galectin-9 positive and cell surface galectin-9 negative cells, and mRNA of the galectin-9 in each cell group was quantified by the real-time RT-PCR. As a result, no statistical difference was observed between these cell groups. After these cells were immobilized and subjected to a treatment for making the cell membranes permeable, they were stained with an anti-galectin-9 antibody so as to stain every galectin-9 contained in the cells. The stained galectin-9 was measured by flow cytometry. Also in this case, no statistical difference was observed between these cell groups.
As revealed by the previous experiments, TH17 differentiation is inhibited strongly by the addition of galectin-9. Also, as already reported, differentiation into TH17 cells is inhibit when cells are cultured under TCR stimulation only or under TH1 and TH2 cell differentiation condition. Thus, the concentrations of galectin-9 in the culture supernatant obtained by culturing the naïve T cells under these conditions were then examined. As a result, the concentration of the galectin-9 was high under the TH1 and TH2 cell differentiation conditions, whereas the galectin-9 was inhibited under the TH17 cell differentiation condition (
From these results, it was found that galectin-9-secreting cells are present in the unskewed system and the TH1 and TH2 differentiation-inducing system. Galectin-9 does not have any signal peptide. The mechanism by which galectin-9 is secreted is totally unknown, but there is no doubt that galectin-9 passes through a cell membrane either directly or via any vehicle from cytoplasm where it is located predominantly. The inventors of the present invention considered that, on cell surfaces of galectin-9-secreting cells, galectin-9 in an intermediate stage of its secretion might be detected. Thus, they stained the galectin-9-secreting cells using an anti-galectin-9 antibody. As a result, the inventors of the present invention successfully detected cell populations expressing galectin-9 on cell surfaces. By the way, this galectin-9 staining was carried out in the presence of lactose. Galectin-9 binds to glycolipids and glycoproteins abundant on cell surfaces. Thus, the staining in the above-described manner was performed in order to discriminate target cells from cells having galectin-9 secondary bound to their cell surfaces after being secreted. As a result of preliminary experiments, it was confirmed that 30 mM lactose completely inhibited the secondary binding of galectin-9 to the cells, whereas it did not interfere with antigen-antibody reactions. Thus, the staining of galectin-9 on cell surfaces was performed always in the presence of 30 mM lactose. A little less than 2% of naïve T cells before being subjected to TCR stimulation expressed galectin-9 on cell surfaces, and as a matter of course, most of them were CD25− cells (
(A) Naïve T cells were prepared from mouse spleen cells, and sorted into cell surface galectin-9 positive cells (THGAL9 cells: Gal-9+ TH) and cell surface galectin-9 negative cells (non-THGAL9 cells: Gal-9− TH). The cells in each cell group were cultured for 96 hours with or without TCR stimulation (an anti-CD28 antibody was added in an anti-CD3 antibody-coated plate), and galectin-9 secreted in each culture supernatant was quantified by ELISA. Galectin-9 secretion was induced by the TCR stimulation only in the THGAL9 cells.
(B) The mRNA expressions of cytokines in each cell group were examined by the real-time RT-PCR. The THGAL9 cells exhibited higher expressions of IL-10 and TGF-β than the non-THGAL9 cells, whereas the THGAL9 cells exhibited lower expressions of IL-4 and IL-17A than the non-THGAL9 cells.
(C) The naïve T cells were cultured for 6 hours under TH17 differentiation-inducing stimulation. Then, the cultured cells were mixed with the THGAL9 cells (Gal-9+ TH) or the non-THGAL9 cells (Gal-9− TH) at a mixing ratio of 1:1. Thereafter, they were co-cultured for 90 hours under TCR stimulation only. IL-17A secreted in the culture supernatant was quantified by ELISA. On the other hand, the mRNA expression of Foxp3 was quantified by the real-time RT-PCR. By the addition of the THGAL9 cells, IL-17A secretion was inhibited, whereas Foxp3 expression was increased.
(D) The above-described co-culture was carried out in the presence of 30 mM lactose (or sucrose as a control) for competitive inhibition of galectin-9. By the addition of the lactose, the inhibition of IL-17A production by the THGAL9 cells was canceled. This result suggests that, although THGAL9 cells produce inhibitory cytokines IL-10 and TGF-β, galectin-9 plays an essential role in inhibition of TH17 differentiation.
(E) In order to prove that IL-10 and TGF-β contribute to the TH17 differentiation inhibitory action by THGAL9 only slightly, neutralizing antibodies against IL-10 and TGF-β were added to the TH17 inhibitory system used in the co-culture of THGAL9 in the above (C) both at a concentration of 10 μg/ml. As a result, these neutralizing antibodies did not inhibit the action of THGAL9.
(F) In order to further clarify the contribution of IL-10, recombinant IL-10 was added to the assay system used in the above (C), and the action thereof on the IL-17 production was examined. IL-10 did not exhibit any statistically significant inhibitory effect in the examined concentration range.
The CD4 T cells expressing cell surface galectin-9 found in the experiment described with reference to
Furthermore, the fact that THGAL9 inhibits TH17 and promotes Treg differentiation was verified by the co-culture experiments. IL-10, which is expressed at a high level by THGAL9, is the most typical inhibitory cytokine, and it has been reported that IL-10 inhibits TH17 differentiation (Non-Patent Document 40). However, the experiments (D, E) using the inhibitors and the experiment (F) using the recombinant IL-10 demonstrated that galectin-9 is a substance chiefly responsible for a drug efficacy for inhibiting the TH17 differentiation induction at least in the assay system used in the experiments described with reference to
(A) Naïve CD4 T cells were cultured for 96 hours under TCR stimulation, and the cultured cells were sorted into CD25+ THGAL9, CD25+ non-THGAL9, and CD25− non-THGAL9. The cells in each cell group were cultured for another 96 hours under TCR stimulation, and galectin-9 in each culture supernatant was quantified by ELISA.
(B) The expressions of IL-10 and TGF-β1 in the cells described in the above (A) were quantified by the real-time RT-PCR.
As a result, by subjecting the THGAL9 cells to repetitive TCR stimulation, increase in galectin-9 secretion and increase in mRNA expressions of IL-10 and TGF-β were observed.
<Addition of Stabilized Galectin-9 Increases THGAL9>
(A)
(B) THGAL9 produces not only galectin-9 but also IL-10 and TGF-β. In order to examine the possibility that these cytokines may be involved in the increase in THGAL9 by TCR stimulation, naïve CD4 T cells were subjected to TCR stimulation in the presence of an IL-10 neutralizing antibody, an IL-10R neutralizing antibody, or a TGF-β neutralizing antibody, and the emergence of THGAL9 cells was examined by flow cytometry. The results thereof are shown in
(C) It is known that IL-10 promotes the differentiation of Tr1, which is an inhibitory T cell, and there is a possibility that IL-10 may affect the increase in THGAL9. From the results obtained in the above (B), it is considered that IL-10 contributes only slightly at least to the increase in THGAL9 by TCR stimulation. Thus, this time, IL-10 (or stabilized human galectin-9 as a control) was added to naïve CD4 T cells, which were then cultured under TCR stimulation, and the emergence of THGAL9 cells was examined by flow cytometry. As a result, in the system of the present experiment, the increase in THGAL9 by IL-10 was not observed.
(A) The reported Tr1 cell markers, namely, LAP, NKG2D, LAG-3, and CTLA-4 of naïve CD4+ T cells were stained so as to examine the association with THGAL9 cells by flow cytometry. CD25−THGAL9 cells expressed all of these Tr1 cell markers, whereas CD25− non-THGAL9 cells expressed none of them.
(B) These cells were subjected to TCR stimulation, and the same measurement was performed with respect to the T cell population found to be CD25 positive. As a result, nearly all the CD25 positive CD4 cells expressed the Tr1 markers.
(C)
(D, E, F) Naïve CD4+ T cells were subjected to TCR stimulation in the presence or absence of IL-27 (25 ng/ml), and cultured for 3 days to promote induction of differentiation into Tr1. Part of the culture supernatant after 3 days of culture was collected, and the concentration of IL-10 (
The CD25−THGAL9 cells before being subjected to the TCR stimulation expressed all the known Tr1 cell markers, but the expressions of these markers were not observed in the CD25−CD4+ non-THGAL9 cells expressing no galectin-9 on cell surfaces (
Thus, in order to further clarity the relationship between THGAL9 and Tr1, cells carrying Tr1 markers were examined in galectin-9 knockout mice, and the results thereof are shown in
(A)
(B)
(C)
These results all demonstrate that THGAL9 and Tr1 are very similar cells, and according to the current definition of Tr1, THGAL9 is the same as Tr1 or a subgroup of Tr1.
Table 1 below shows the results of examining the proportion of cell surface galectin-9 positive cells (THGAL9) in CD4 positive T cells collected from various organs. In Table 1, “Organs” means the “organs”; “Thymus” means the “thymus”; “LN” means the “lymph node”; “Spleen” means the “spleen”; “Peyer's patch” means the “Peyer's patch”; and “PBMC” means “peripheral blood mononuclear cells”. Also, “Phenotype” means the “phenotype”, and “cells” means the “cells”. In the thymus, a large number of T cells are in an immature state showing double positive for CD4 and CD8, so that only CD4 SP (CD4 single positive) T cells were examined in the present experiment. Also, the presence of THGAL9 cells was examined in various lymphoid organs. As a result, it was found that about ¼ of the CD4 single positive cells were THGAL9 cells in the thymus; and about 4%, 7%, 15%, and 7% of CD4+CD25− T cells derived from the lymph node, spleen, peripheral blood and Peyer's patch, respectively, were THGAL9 cells.
<Effects of Galectin-9 on Human TH17/Treg Differentiation and Identification of Human THGAL9 Cells>
It is well known that the immune system of humans is not the same as that of mice. Accordingly, there is no guarantee that galectin-9 functions clarified in this research using mice and mouse cells also apply to humans. Thus, in considering clinical applications of galectin-9, it is essential to verify that: galectin-9 controls the TH17/Treg balance also in humans; and humans also have THGAL9 cells.
(A) To peripheral blood CD4+ T cells obtained from four healthy subjects, stabilized human galectin-9 (30 nM) or PBS as a control was added. The cells were cultured under TCR stimulation for 96 hours. CD25 was stained and measured by flow cytometry.
(B) CD25 and Foxp3 of the cells obtained in the above (A) were stained, and the expressions of CD25 and Foxp3 were measured by flow cytometry.
(C) To human CD4+ T cells, stabilized human galectin-9 (30 nM) or PBS as a control was added. The cells were cultured for 9 days under the TH17-differentiation-inducing stimulation. The IL-17 concentration in the culture supernatant was quantified by ELISA.
(D) Human CD4+ T cells were cultured for 96 hours under TCR stimulation or without stimulation. Cell surface galectin-9 and CD25 of the cells were stained, and measured by flow cytometry.
(E) Human CD4+ T cells were cultured for 96 hours under TCR stimulation. The cultured cells were then sorted into cell surface galectin-9 positive cells (CD25+ THGAL9) and cell surface galectin-9 negative cells (CD25+ non-THGAL9). The cells in each cell group were cultured for another 96 hours under TCR stimulation. Galectin-9 in each culture supernatant was quantified by ELISA. On the other hand, the mRNA expressions of the respective cytokines indicated in
When the CD4+ T cells obtained from the human peripheral blood were cultured in the presence of galectin-9, the proportions of the CD25 positive cells and CD25+Foxp3+ cells were increased by galectin-9, and the increase was further enhanced by TCR stimulation (
According to the present example, it was verified that THGAL9 secretes galectin-9 and can serve as a cell for adjusting TH17/Treg balance. The fact that galectin-9 exhibits the same actions in mice and humans is a very important finding in clinical application of galectin-9, especially stabilized galectin-9. Moreover, from the fact that THGAL9 is present also in humans, it is considered that immune regulation by galectin-9 is well conserved across animal species. THGAL9 can be detected by detecting galectin-9 on a cell surface. Thus, as shown in
<Cells Expressing Galectin-9 on Cell Surfaces, Other than THGAL9>
It has been revealed that administration of stabilized human galectin-9 exhibits a drug efficacy not only in the above-described autoimmune disease models but also various disease models. In these cases, there is a possibility that the administered galectin-9 might trigger the induction of cells that secrete galectin-9 including THGAL9 galectin-9. THGAL9 was identified as a cell expressing galectin-9 on a cell surface, and it was verified that THGAL9 has a galectin-9-secreting ability. The inventors of the present invention considers that galectin-9 on a cell surface is detected while it is in an intermediate stage of its secretion, and it is thus expected that galectin-9-expressing cells other than THGAL9 can be searched for using the cell surface galectin-9 expression as an indicator. The state where galectin-9 is exposed at least on a cell surface results from the fact that the galectin-9 already has been translocated through the cell membrane, and in a broad sense, the galectin-9 in this state is “secreted”. Thus, in various disease models, the presence of a cell group expressing galectin on cell surfaces was examined.
<Effect of Stabilized Galectin-9 in Peritonitis Model and Cell Surface Galectin-9 Expressing Cells Induced at this Time>
Also in this serious peritonitis, the survival rate of the mice was improved significantly by the single administration of the stabilized galectin-9 immediately after CLP or 24 hours after CLP. However, this effect was not observed in the nude mice (
(A)
(B)
(C)
Also in this cancer-carrying model, when the administered stabilized galectin-9 exhibited a drug efficacy, cells expressing galectin-9 on cell surfaces emerged as described above. This suggests that transferring these cells would be useful in cancer treatment. This also suggests the possibility that it might be possible to diagnose cancer progression or a treatment effect by using these cells as a marker.
The following items were measured over time: the volume of the pedal edema in hind paws (once a week; measured using PLETHYSMOMETER as in the experiment described with reference to
In an experiment to be described with reference to
CD4 T cells are deeply involved in maturation of B cells, and in particular, it is said that a CD4 positive cell called “follicular B helper T cell” (TFH) plays a major role. Thus, in an experiment to be described with reference to
The cell surface galectin-9 expression was particularly high in ICOS−CXCR5+ CD4 positive cells and ICOS+CXCR5− CD4 positive cells. This suggests the possibility that these cells secrete galectin-9 and control the antibody production.
This suggests the possibility that these cell groups expressing galectin-9 on cell surfaces might be useful in treatment and diagnosis of autoimmune diseases including systemic erythematous.
The inventors further discovered that THGAL9 is increased by adding stabilized human galectin-9. That is, it is considered that the administered stabilized human galectin-9 exhibits, in addition to the direct action thereof, an action of inducing THGAL9, and the thus-induced THGAL9 acts on various cells by secreting a necessary amount of galectin-9 in a localized region. This provides consistent explanation for the long-lasting immune regulatory activity of stabilized galectin-9. Furthermore, the inventors of the present invention considered that cell surface galectin-9 is in an intermediate stage of its secretion, and using the expression of cell surface galectin-9 as an indicator, they discovered various cell populations that secrete (or may secrete) galectin-9, other than THGAL9. These cells are considered to regulate immunity by secreting galectin-9, similarly to THGAL9.
<Administration of Galectin-9 Allows Prolonged Survival of LLC Cancer-Carrying Mice, and pDC-Like Macrophages is Increased at this Time>
As shown in
(A) To abdominal cavities of C57BL/6 mice (♀, 7- to 10-week old), 5×105 cells of a mouse lung cancer-derived tumor cell line LLC were inoculated (day 0). From the day of the inoculation, stabilized human galectin-9 (control: PBS) was administered intraperitoneally to the mice three times a week at a dose of 30 μg.
(B)
<Galectin-9 Promotes Differentiation of CD11c Positive Cells with M-CSF in Test Tube in Tim-3 Independent Manner>
As shown in
(A) Bone marrow cells were washed out from femora and tibiae of mice. They were cultured for 2 hours in a RPMI-1640 medium containing 10% fetal bovine serum and an antibiotic, and adherent cells (mature macrophages) were removed. The remaining bone marrow cells were cultured for 7 days in a medium containing GM-CSF (Peprotech, 20 ng/ml) or M-CSF (R&D Systems, 20 ng/ml). This time, non-adherent cells were removed by washing, and the adherent cells were analyzed by flow cytometry. From the fact that more than 95% of the adherent cells were double positive for F4/80 and CD11b, these adherent cells were determined to be mature macrophages.
(B)
<CD11c Positive Cells Differentiated with Galectin-9 and M-CSF are pDC-Like Macrophage Precursor Cells>
(A) Analysis by flow cytometry revealed that the galectin-9 increased the expressions of B220 and I−A/I−E and decreased the expression of CD14. On the other hand, F4/80 used widely as a macrophage marker was expressed at a high level despite the addition of the galectin-9, and maintained the macrophage phenotype.
(B) mRNAs of transcription factors were analyzed by the real-time RT-PCR. As a result, IRF4 and IRF8 necessary for differentiation into dendritic cells were increased by the galectin-9. Also, SpiB, which is considered to be expressed in pDC precursor cells, was increased by the galectin-9, and Id2, which is considered to inhibit the transcription factor E2-2 of mature pDC, also was increased by the addition of the galectin-9.
(C) Furthermore, mRNAs of TLR7, TLR8, and TLR9 also were increased by the addition of the galectin-9.
(D) Macrophages were differentiated for 7 days in the presence of M-CSF and galectin-9. Thereafter, the TLR agonists indicated in
From these results, it is considered that the macrophages differentiated with M-CSF and the stabilized human galectin-9 had not yet become mature pDC although they exhibited a phenotype similar to pDC. Thus, they are considered to be pDC-like macrophage precursors. Accordingly, it is suggested that galectin-9 induces differentiation of macrophages to pDC-like macrophages.
<CD11c Positive Cells Differentiated with Galectin-9 and M-CSF are Matured to pDC-Like Macrophages by LPS Stimulation>
As shown in
(A) From the results of the previous experiments, it was found that galectin-9 differentiates macrophages differentiated with M-CSF to cells having presumably a phenotype of pDC-like macrophage precursors. This time, whether or not the differentiation of these cells into pDC-like macrophages is caused to proceed by LPS stimulation was examined. The macrophages differentiated with M-CSF and galectin-9 by the method described with reference to
(B) Macrophages differentiated with M-CSF and galectin-9 by the method of
(C)
From these results, it was verified that macrophages having differentiated to cells considered to be pDC-like macrophage precursors with galectin-9 exhibit the mature pDC-like macrophage phenotype by LPS stimulation.
(A) It is known that pDC expresses a high level of type I interferon. Thus, whether or not pDC-like macrophages maturated in vitro secrete IFN-α and IFN-β (typical type I interferons) was examined by ELISA. To pDC-like macrophages subjected to LPS stimulation for 24 hours by the method described with reference to
(B)
From these results, it was verified that galectin-9 promotes the differentiation into pDC-like macrophages in vitro, and also that, by maturing these cells with LPS, the anti-cancer actions via the activation of NK cells is enhanced. As shown in
Table 2 below shows the result of analyzing various pharmacokinetic parameters by moment analysis, based on the results of the examination on blood kinetics of stabilized human galectin-9 (
As specifically described above, the cell of the present invention (e.g., THGAL9 cell or the like) can contribute to, for example, treatment or reduction of symptoms of autoimmune diseases, allergic diseases, tumors, and other diseases through immune regulation via secretion of galectin-9 in vivo. Furthermore, galectin-9 on a cell surface of the cell of the present invention can serve as an excellent marker for identifying a type 1 T regulatory cell (Tr1 cell) that secretes galectin-9 and IL-10, for example. Thus, by utilizing this marker, the cell of the present invention can be applied to Tr1 cell separation.
The present invention is by no means limited by the above descriptions and the above embodiments and examples. Various changes and modifications may be made without departing from the scope of the present invention.
SEQUENCE LISTINGTF11056WO Sequence List 2011.12.09.5T25.txt
Claims
1. A cell not comprising DNA coding for galectin-9 having a signal peptide, wherein
- the cell has an ability to secrete galectin-9 and expresses the galectin 9 on a cell surface.
2. The cell according to claim 1, which is a T cell.
3. The cell according to claim 2, which is a CD4 positive T cell.
4. The cell according to claim 3, which is a follicular B helper T cell (TFH cell).
5. The cell according to claim 3, wherein increase in expression level of CD25 and secretion of at least one of galectin-9 and interleukin 10 (IL-10) are induced by T cell receptor (TCR) stimulation.
6. The cell according to claim 3, which does not express Foxp3.
7. The cell according to claim 2, which is a γδT cell.
8. The cell according to claim 1, which is a natural killer cell (NK cell).
9. The cell according to claim 1, which is a B cell.
10. The cell according to claim 1, which is a NKT cell.
11. The cell according to claim 1, which is a conventional dendritic cell (cDC).
12. The cell according to claim 1, which is a plasmacytoid dendritic cell (pDC).
13. The cell according to claim 1, which is a pDC-like macrophage (pDC-Mφ.
14. A method for producing the cell according to claim 1, the method comprising:
- administering galectin-9 to an animal, thus inducing galectin-9 expression on a cell surface of at least one cell in the animal.
15. A method for producing the cell according to claim 1, the method comprising:
- culturing one or more cells of an animal in the presence of galectin-9, thus inducing galectin-9 expression on a cell surface of at least one of the cells.
16. The production method according to claim 15, wherein
- the cells of the animal comprise a cell expressing galectin-9 on a cell surface, and
- by culturing the cells in the presence of galectin-9, the proportion of the cell expressing galectin-9 on the cell surface is increased.
17. The production method according to claim 14, wherein the animal is a mammal.
18. The production method according to claim 17, wherein the mammal is a human.
19. A pharmaceutical agent comprising:
- at least one selected from the group consisting of: the cell according to claim 1; homogenates of the cell; and extracts of the cell.
20. The pharmaceutical agent according to claim 19, for use in treatment or reduction of a symptom of a disease caused by deficiency or absence of physiological activity or biological activity of galectin-9.
21. The pharmaceutical agent according to claim 19, which is a diagnostic agent for use in diagnosis of the presence or absence of a cell that contains galectin-9 or a galectin-9-binding substance.
22. The pharmaceutical agent according to claim 19, which is an immunomodulatory agent.
23. The pharmaceutical agent according to claim 19, which is an anti-tumor agent.
24. The pharmaceutical agent according to claim 23, wherein the tumor is a malignant tumor.
25. The pharmaceutical agent according to claim 24, wherein the malignant tumor is an epithelial malignant tumor.
26. The pharmaceutical agent according to claim 24, wherein the malignant tumor is a non-epithelial malignant tumor.
27. The pharmaceutical agent according to claim 26, wherein the non-epithelial malignant tumor is at least one of a tumorigenic non-epithelial malignant tumor and a non-tumorigenic non-epithelial malignant tumor.
28. The pharmaceutical agent according to claim 24, wherein the malignant tumor is at least one selected from the group consisting of skin cancers, melanomas, breast cancers, ovarian cancers, uterine cancers, malignant testicular tumors, prostate cancers, bladder cancers, kidney cancers, thyroid cancers, pharyngeal and laryngeal cancers, tongue cancers, maxillary cancers, esophageal cancers, stomach cancers, colon and rectal cancers, lung and bronchial cancers, liver cancers, hepatocellular cancers, intrahepatic bile duct cancers, extrahepatic bile duct and gallbladder cancers, pancreatic cancers, leukemia, malignant lymphoma, plasmacytoma, sarcoma, osteosarcoma, chondrosarcoma, leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, malignant hemangioma, malignant hemangioendothelioma, brain tumors, meningioma, glioma, and astrocytoma.
29. The pharmaceutical agent according to claim 19, which is an anti-allergic agent.
30. The pharmaceutical agent according to claim 19, which is an anti-autoimmune disease agent.
31. The pharmaceutical agent according to claim 19, which is an anti-inflammatory agent.
32. The pharmaceutical agent according to claim 19, which is an alternate agent for adrenocortical steroid hormone.
33. The pharmaceutical agent according to claim 19, which is an inhibitor for transplantation rejection accompanying transplantation of a cell, a tissue, or an organ.
34. The pharmaceutical agent according to claim 19, for use in treatment or reduction of a symptom of sepsis.
35. The pharmaceutical agent according to claim 19, for use in treatment or reduction of a symptom of an infectious disease.
36. A method for diagnosing the presence or absence of galectin-9 or a galectin-9-binding substance in a test cell using at least one selected from the group consisting of: the cell according to claim 1; homogenates of the cell; and extracts of the cell.
37. A method for treating a disease of an animal or reducing a symptom caused by the disease, the method comprising the step of:
- administering to the animal at least one selected from the group consisting of: the cell according to claim 1; homogenates of the cell; and extracts of the cell.
38. The method according to claim 37, wherein the animal is a mammal.
39. The method according to claim 38, wherein the mammal is a human.
40. The method according to claim 37, wherein the disease is caused by the deficiency or absence of physiological activity or biological activity of galectin-9.
41. The method according to claim 37, wherein the disease is caused by immune abnormality.
42. The method according to claim 37, wherein the disease is an autoimmune disease.
43. The method according to claim 37, wherein the disease is a tumor.
44. The method according to claim 43, wherein the tumor is a malignant tumor.
45. The method according to claim 44, wherein the malignant tumor is an epithelial malignant tumor.
46. The method according to claim 44, wherein the malignant tumor is a non-epithelial malignant tumor.
47. The method according to claim 46, wherein the non-epithelial malignant tumor is at least one of a tumorigenic non-epithelial malignant tumor and a non-tumorigenic non-epithelial malignant tumor.
48. The method according to claim 44, wherein the malignant tumor is at least one selected from the group consisting of skin cancers, melanomas, breast cancers, ovarian cancers, uterine cancers, malignant testicular tumors, prostate cancers, bladder cancers, kidney cancers, thyroid cancers, pharyngeal and laryngeal cancers, tongue cancers, maxillary cancers, esophageal cancers, stomach cancers, colon and rectal cancers, lung and bronchial cancers, liver cancers, hepatocellular cancers, intrahepatic bile duct cancers, extrahepatic bile duct and gallbladder cancers, pancreatic cancers, leukemia, malignant lymphoma, plasmacytoma, sarcoma, osteosarcoma, chondrosarcoma, leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, malignant hemangioma, malignant hemangioendothelioma, brain tumors, meningioma, glioma, and astrocytoma.
49. The method according to claim 37, wherein the disease is an allergic disease.
50. The method according to claim 37, wherein the disease is transplantation rejection accompanying transplantation of a cell, a tissue, or an organ.
51. The method according to claim 37, wherein the disease is sepsis.
52. The method according to claim 37, wherein the disease is an infectious disease.
53. The method according to claim 37, wherein the symptom caused by the disease is inflammation.
54. A method for regulating immunity of an animal, the method comprising the step of:
- administering the cell according to claim 1 to the animal.
55. A method for detecting the cell according to claim 1, the method comprising the step of:
- detecting the galectin-9 expressed on the cell surface of the cell as a marker.
56. The cell detection method according to claim 55, wherein the cell according to claim 1 is an IL-10-producing type 1 regulatory T cell (Tr1 cell).
57. The cell detection method according to claim 55, wherein the cell according to claim 1 is a regulatory immune cell.
58. A method for diagnosing a disease of an animal or a symptom caused by the disease, the method comprising the step of:
- in a tissue of the animal containing or not containing the cell according to claim 1, detecting the cell according to claim 1 qualitatively or quantitatively by detecting the galectin-9 expressed on the cell surface of the cell as a marker.
59. A method for determining a therapeutic effect on a disease of an animal, the method comprising the steps of:
- treating the disease of the animal;
- diagnosing the disease or a symptom caused by the disease by the diagnostic method according to claim 58 before and after the treatment; and
- comparing diagnostic results obtained before and after the treatment.
60. A cell separation method comprising the steps of:
- in a tissue of an animal containing the cell according to claim 1, detecting the cell by detecting the galectin-9 expressed on the cell surface of the cell as a marker; and
- separating the detected cell from other cells in the tissue of the animal.
61. A method for producing the cell according to claim 1, comprising the step of:
- separating the cell according to claim 1 from a tissue of an animal by a cell separation method comprising the steps of:
- in a tissue of the animal containing the cell according to claim 1, detecting the cell by detecting the galectin-9 expressed on the cell surface of the cell as a marker; and
- separating the detected cell from other cells in the tissue of the animal.
62. A method for producing the cell according to claim 1, the method comprising:
- administering galectin-9 to an animal, thus inducing galectin-9 expression on a cell surface of at least one cell in the animal, and
- separating the cell according to claim 1 from a tissue of the animal by a cell separation method comprising the steps of:
- in a tissue of the animal containing the cell according to claim 1, detecting the cell by detecting the galectin-9 expressed on the cell surface of the cell as a marker; and
- separating the detected cell from other cells in the tissue of the animal.
Type: Application
Filed: Dec 9, 2011
Publication Date: Dec 5, 2013
Inventors: Mitsuomi Hirashima (Takamatsu-shi), Toshiro Niki (Takamatsu-shi), Tomohiro Arikawa (Kanazawa-shi), Souichi Oomizu (Kida-gun), Takeshi Kadowaki (Takamatsu-shi)
Application Number: 13/992,018
International Classification: C12N 5/0783 (20060101); A61K 49/00 (20060101); A61K 35/14 (20060101); G01N 33/50 (20060101); C12N 5/0781 (20060101); C12N 5/0784 (20060101);
